ID,LABEL,Parent,definition,definition source,term editor,alternative label,seeAlso,CVX code,editor note,VAC adjuvant ID,term tracker item,has molecular receptor,has role,induces immune profile,equivalent axioms
ID,A rdfs:label,C %,A definition SPLIT=|,A definition source SPLIT=|,A term editor SPLIT=|,A alternative label SPLIT=|,A rdfs:seeAlso SPLIT=|,A 'CVX code' SPLIT=|,A editor note SPLIT=|,A 'VAC adjuvant ID',A term tracker item SPLIT=|,C 'has molecular receptor' some % SPLIT=|,C 'has role' some % SPLIT=|,C 'induces immune profile' some % SPLIT=|,EC %
VO:0000580,vaccine adjuvant,,A vaccine component that is chemical substance added to vaccine and enhance and direct immune response to protective antigen. Many of vaccine adjuvants cause a range of serious side-effects.,,Oliver He,,,,,,,,,,'vaccine component' and ('has role' some 'vaccine adjuvant role')
VO:0000093,mineral salt vaccine adjuvant,vaccine adjuvant,A vaccine adjuvant that is formed as a mineral salt.,,Samantha G. Sayers|Oliver He,,,119,,,,,,,
VO:0000118,microbial derivative vaccine adjuvant,vaccine adjuvant,A vaccine adjuvant that contains microbial derived material.,,Oliver He|Samantha G. Sayers,,,52|83,,,,,,,
VO:0000127,aluminum hydroxide vaccine adjuvant,aluminum vaccine adjuvant,An aluminum vaccine adjuvant that contains aluminum hydroxide.,,Oliver He,alum,,,,,,,,,
VO:0000128,aluminum phosphate vaccine adjuvant,aluminum vaccine adjuvant,An aluminum vaccine adjuvant that is aluminum phosphate.,,Oliver He|Samantha G. Sayers,Adju-Phos®|Al(PO)4,,,,,,,,,
VO:0000131,calcium phosphate vaccine adjuvant,mineral salt vaccine adjuvant,A mineral salt vaccine adjuvant composed of calcium phosphate.,,Oliver He|Samantha G. Sayers,CaHPO4,,,,,,,,,
VO:0000133,Freund's emulsified oil adjuvant,emulsion vaccine adjuvant,"An emulsion vaccine adjuvant that consists of a water-in-oil emulsion of aqueous antigen in paraffin (mineral) oil of low specific gravity and low viscosity. It is named after Jules T. Freund (1890-1960), Hungarian-born American immunologist. It is a water in oil emulsion.",,Oliver He|Samantha G. Sayers,,,,,,,,,,
VO:0000139,complete Freund's adjuvant,Freund's emulsified oil adjuvant,"A Freund's emulsified oil adjuvant that contains inactivated and dried mycobacteria, usually Mycobacterium tuberculosis (the pathogenic agent of tuberculosis).",,Oliver He,,,,,,,,,,
VO:0000142,incomplete Freund's adjuvant,Freund's emulsified oil adjuvant,A Freund's emulsified oil adjuvant that does not contain the mycobacterial components.,,Oliver He,,,,,,,,,,
VO:0000143,cholera toxin vaccine adjuvant,microbial derivative vaccine adjuvant,A microbial derivative vaccine adjuvant consisting of cholera toxin (CT) from Vibrio cholerae.,,Oliver He|Samantha G. Sayers,CT|cholera toxin,,,,,,,,,
VO:0000146,Corynebacterium-derived P40 vaccine adjuvant,microbial derivative vaccine adjuvant,A microbial derivative vaccine adjuvant that is the P40 particulate fraction isolated from Corynebacterium.,PMID:8447157,Oliver He|Samantha G. Sayers,,,,,,,,,,
VO:0000181,lipopolysaccharide vaccine adjuvant,microbial derivative vaccine adjuvant,A microbial derivative vaccine adjuvant made from bacterial lipopolysaccharide (LPS) of gram-negative bacteria.,,Oliver He|Samantha G. Sayers,LPS vaccine adjuvant,,,,,,,,,
VO:0000187,muramyl dipeptide vaccine adjuvant,synthetic vaccine adjuvant,A synthetic vaccine adjuvant formulated to correspond to a component found in a water-soluble extract of cell walls of mycobacteria used in complete Freund's adjuvant (CFA).,PMID:344799,Oliver He|Samantha G. Sayers,MDP|muramyl dipeptide,,,,,,,,,
VO:0000190,squalene vacccine adjuvant,emulsion vaccine adjuvant,An emulsion vaccine adjuvant that contains an organic polymer with some antigenic epitopes which might be shared with other organic polymers acting as immunostimulators.,,Oliver He|Samantha G. Sayers,squalene,,,,,,,,,
VO:0000191,arlacel A vaccine adjuvant,synthetic vaccine adjuvant,A synthetic vaccine adjuvant that is an emulsifier called Arlacel A.,PMID:2042393,Oliver He|Samantha G. Sayers,arlacel A,,,,,,,,,
VO:0000192,Montanide 103 vaccine adjuvant,Montanide vaccine adjuvant,A Montanide vaccine adjuvant that is Montanide 103.,,Oliver He,Montanide 103,,,,,,,,,
VO:0000193,Bordetella pertussis component vaccine adjuvant,microbial derivative vaccine adjuvant,A microbial derivitive vaccine adjuvant that contains components from killed Bordetella pertussis. The killed B. pertussis has a strong adjuvant effect on the diphtheria and tetanus toxoids in the DPT vaccines.,,Oliver He,,,,,,,,,,
VO:0000351,Adjumer vaccine adjuvant,synthetic vaccine adjuvant,A synthetic vaccine adjuvant that is PCPP salt.,PMID:75551218,Samantha G. Sayers,Adjumer|PCPP salt|polyidi (carboxylatophenoxy) lphosphazene|polyphosphazene,,,,,,,,,
VO:0000366,liposome-based vaccine adjuvant,particulate antigen delivery system,"A particulate antigen delivery system that contains particles made up of concentric lipid membranes containing phospholipids and other lipids in a bilayer configuration separated by aqueous compartments. It is a relatively stable but non-covalently-bound complex of saponin adjuvant Quil-A, cholesterol and amphipathic antigen in a molar ratio of approximately 1:1:1. The spectrum of viral capsid antigens and non-viral amphipathic antigens of relevance for human vaccination, incorporated into ISCOMs, comprises influenza, measles, rabies, gp340 from EB-virus, gp120 from HIV, Plasmodium falciparum and Trypanosoma cruzi.",http://www.vaccination.inoz.com/adjuvants.html,Oliver He,,,,,,,,,,
VO:0000384,IL-15 plasmid vaccine adjuvant,IL-15 vaccine adjuvant,,"PMID:18472194
",Oliver He,,,,,,,,,,
VO:0000388,E. coli LT toxin derived vaccine adjuvant,microbial derivative vaccine adjuvant,A microbial derivative vaccine adjuvant that is derived from E. coli heat labile toxin LT.,,Oliver He|Samantha G. Sayers,,,,,,,,,,
VO:0000559,adamantylamide dipeptide vaccine adjuvant,synthetic vaccine adjuvant,"A synthetic vaccine adjuvant, adamantylamide dipeptide (AdDP) is the desmuramyl analog of MDP.",PMID:8375945,Oliver He|Samantha G. Sayers,AdDP,,,,,,,,,
VO:0000757,ISCOM vaccine adjuvant,particulate antigen delivery system,"A particulate antigen delivery system that consists of an assembly of antigens in multimeric form and presents an antigen to induce specific immunologic responses. The assembly is attached to a matrix with a built-in adjuvant, saponin. ISCOMs induce strong serum antibody responses, and are used as highly immunogenic forms of subunit vaccines. MeSH term: D20.215.894.860.449.",,Oliver He,ISCOM|The immunostimulating complex,,,,,,,,,
VO:0000884,aluminum vaccine adjuvant,mineral salt vaccine adjuvant,A mineral salt vaccine adjuvant that is composed of some aluminum compound.,,Oliver He,,,,,,,,,,
VO:0000938,xanthan gum vaccine ajuvant,synthetic vaccine adjuvant,"A synthetic vaccine adjuvant that is derived from Xanthomonas campestris, has a pentasaccharide repeating unit structure, and its terminus contains a mannose moiety which acts as a toll-like receptor 2 agonist.",PMID:19608270|http://www.sciencedirect.com/science/article/pii/S0142961209006371,Asiyah Yu Lin,,,,,,,,,,
VO:0001147,IL-12 vacince adjuvant,cytokine vaccine adjuvant,A cytokine vaccine adjuvant that contains IL-12.,,Oliver He|Allen Xiang,,,,,,,,,,
VO:0001237,CpG DNA vaccine adjuvant,microbial derivative vaccine adjuvant,A microbial derivative vaccine adjuvant compsed of CpG DNA.,PMID:12899580,Oliver He,,,,,,,,,,
VO:0001238,Ribi vaccine adjuvant,emulsion vaccine adjuvant,An emulsion vaccine adjuvant that is a stable oil-in-water emulsion.,http://www.sigmaaldrich.com/catalog/ProductDetail.do?D7=0&N5=SEARCH_CONCAT_PNO%7CBRAND_KEY&N4=M6661%7CSIGMA&N25=0&QS=ON&F=SPEC,Samantha G. Sayers,,,,,,,,,,
VO:0001239,RC529 vaccine adjuvant,synthetic vaccine adjuvant,A synthetic vaccine adjuvant named RC529 that is a lipid A mimetic.,PMID:16204643,Samantha G. Sayers,,,,,,,,,,
VO:0001240,aluminum potassium sulfate adjuvant,aluminum vaccine adjuvant,An aluminum vaccine adjuvant that is aluminum potassium sulfate (AlK(SO4)2).,,Allen Xiang|Samantha G. Sayers,,,,,,,,,,
VO:0001241,Alhydrogel vaccine adjuvant,aluminum hydroxide vaccine adjuvant,An aluminum hydroxide vaccine adjuvant that is a gel that is made by precipitation of aluminum hydroxide Al(OH)3 under alkaline conditions.,PMID:7551218,Allen Xiang|Samantha G. Sayers,Alhydrogel,,,,,,,,,
VO:0001242,cholera toxin B subunit vaccine adjuvant,cholera toxin derived vaccine adjuvant,A cholera toxin derived vaccine adjuvant made of the B subunit of the cholera toxin from Vibrio cholerae.,,Samantha G. Sayers,CTB|cholera toxin B,,,,,,,,,
VO:0001249,RC529-AF vaccine adjuvant,RC529 vaccine adjuvant,An aqueous formula of the synthetic vaccine adjuvant RC529.,PMID: 15308371,,RC529 vaccine adjuvant in an aqueour formulation,,,"RC529-AF can be obtained from Corixa Corporation (Seattle, WA).",,,,,,
VO:0001250,monophosphoryl lipid A vaccine adjuvant,microbial derivative vaccine adjuvant,A microbial derivative vaccine adjuvant derived from the lipopolysaccharide (LPS) of Salmonella minnesota R595.,PMID:7551218|https://www.frontiersin.org/articles/10.3389/fimmu.2020.577823,Samantha G. Sayers,3-O-deacylated monophosphoryl lipid A vaccine adjuvant|3D-MLA|MPL vaccine adjuvant,PMID:10768940,,,,,,,,
VO:0001251,LTK63 vaccine mutant,E. coli LT toxin derived vaccine adjuvant,An E. coli LT toxin derived vaccine adjuvant that is a mutant form of LT containing a Ser-Lys substitution in position 63 which has been shown to be totally devoid of toxicity stable to protease treatment and able to act as mucosal adjuvant.,PMID:9607006,Samantha G. Sayers,,PMID:10790422|PMID:17920733,,LTK63 is an enzymatically inactive mutant of the heat-labile enterotoxin of Escherichia coli. It can be used as a potent mucosal adjuvant.,,,,,,
VO:0001259,killed Corynebacterium parvum vaccine adjuvant,microbial derivative vaccine adjuvant,A microbial derivative vaccine adjuvant derived from heat-killed Corynebacterium parvum.,PMID:5483667,Samantha G. Sayers,,PMID:4596278|PMID:7591056,,,,,,,,
VO:0001260,Titermax Gold vaccine adjuvant,emulsion vaccine adjuvant,"An emulsion vaccine adjuvant which is a water-in-oil adjuvant with CRL-8300 (a block copolymer), squalene, and sorbitan monooleate.",,Samantha G. Sayers,Titermax Gold,URL: http://www.titermax.com/i_gold4.htm,,,,,,,,
VO:0001261,DDA vaccine adjuvant,synthetic vaccine adjuvant,"A synthetic vaccine adjuvant that is dimethyldioctadecylammonium bromide (DDA), a lipophilic quaternary ammonium salt known as a good adjuvant when co-administered systemically or nasally with an antigen.",,Samantha G. Sayers,Dimethyl dioctadecyl ammonium bromide,PMID:1439129,,,,,,,,
VO:0001262,cationic liposomal vaccine adjuvant DDA:TDB,liposome-based vaccine adjuvant,A liposome-based vaccine adjuvant that have a positive surface charge.,,Samantha G. Sayers,,PMID:19874860,,,,,,,,
VO:0001263,QuilA vaccine adjuvant,tensoactive compound vaccine adjuvant,A tenosactive compound vaccine adjuvant that contains purified extract from the bark of the South American tree Quillaja saponaria Molina.,PMID:7551218,Samantha G. Sayers,,,,,,,,,,
VO:0001264,AS02 vaccine adjuvant,combination vaccine adjuvant,"A combination vaccine adjuvant comprised of monophosphoryl lipid A (MPL), QS21 and an oil in water emulsion.",,Samantha G. Sayers,,PMID:15780441|PMID:15187142,,"monophosphoryl lipid A (MPL), QS21 and an oil in water emulsion.",,,,,,
VO:0001265,AS04 vaccine adjuvant,combination vaccine adjuvant,A combination vaccine adjuvant that is a combination of 50 μg of the immunoenhancer MPL (3-O-desacyl-4′-monophosphoryl lipid A) with 500 μg of aluminium salt.,PMID:21527299,Samantha G. Sayers,,,,,,,,,,
VO:0001266,VSA-3 vaccine adjuvant,emulsion vaccine adjuvant,An emulsion vaccine adjuvant which is an emulsion plus DDA.,PMID:16187717,Samantha G. Sayers,Emulsigen D|VSA-3,,,,,,,,,
VO:0001267,saponin vaccine adjuvant,tensoactive compound vaccine adjuvant,"A tensoactive compound vaccine adjuvant that is derived from saponin, a compound that is an immunostimulator found in the plant P. senega.",,,,,,,,,,,,
VO:0001268,Montanide ISA 720 vaccine adjuvant,Montanide vaccine adjuvant,A Montanide vaccine adjuvant that is formulated as water-in-oil emulsions and induces high antibody titers in several animal species. It is a vaccine adjuvant composed of metabolizable oil and a surfactant system designed to make a water-in-oil emulsion. It has been used since 1992 in more than 50 clinical trials related to therapeutic vaccines against various diseases such as cancer and malaria.,"WEB: http://www.seppic.com/human-health/vaccine-adjuvant/montanide-isa-720-@/view-1044-seproduit.html?menuid=,979,&lang=en",Oliver He|Samantha G. Sayers,Montanide ISA 720|Montanide ISA 720 VG,PMID:15752840,,,,,,,,
VO:0001269,Montanide incomplete Seppic adjuvant,Montanide vaccine adjuvant,A Montanide vaccine adjuvant that is a mineral oil adjuvant.,,,,,,,,,,,,
VO:0001270,Montanide ISA51 vaccine adjuvant,Montanide vaccine adjuvant,A Montanide vaccine adjuvant that is a vaccine adjuvant composed of a light mineral oil and a surfactant system designed to make a water-in-oil emulsion.,"WEB: http://www.seppic.com/human-health/vaccine-adjuvant/montanide-isa-51-@/view-1042-seproduit.html?menuid=,979,&lang=en",Samantha G. Sayers,Montanide ISA51,,,,,,,,,
VO:0001271,Montanide vaccine adjuvant,emulsion vaccine adjuvant,An emulsion vaccine adjuvant developed by Montanide.,http://www.montanide.com/,Oliver He|Samantha G. Sayers,,,,,,,,,,
VO:0001272,EtxB vaccine adjuvant,E. coli LT toxin derived vaccine adjuvant,An E. coli LT toxin derived vaccine adjuvant composed of the B subunit of E. coli heat-labile toxin.,,Oliver He|Samantha G. Sayers,B subunit of E. coli heat-labile enterotoxin,,,,,,,,,
VO:0001273,Polygen vaccine adjuvant,synthetic vaccine adjuvant,A synthetic vaccine adjuvant with the tradename Polygen.,,Oliver He|Samantha G. Sayers,,URL: http://www.mvp-technologies.com/adjuvants/Polygen%20Final%20Technical%20Bulletin.pdf,,,,,,,,
VO:0001285,Algal Glucan vaccine adjuvant,carbohydrate vaccine adjuvant,"A carbohydrate vaccine adjuvant, which enhances both humoral and cell-mediated immunity to oligopeptides in experimental animal models.",PMID:7551218,Samantha G. Sayers,,,,,,,,,,
VO:0001286,Algammulin vaccine adjuvant,combination vaccine adjuvant,A combination vaccine adjuvant that suspension of 1-2μm ovoids of immune stimulant gamma inulin (g-IN) in which alum is embedded as a carrier for protein or other anionic antigens.,PMID:1887671,Samantha G. Sayers,,,,,,,,,,
VO:0001287,BAY R1005 vaccine adjuvant,synthetic vaccine adjuvant,A synthetic vaccine adjuvant that is Bay R1005 (N-(2-Deoxy-2-L-leucylamino β-D-glucopyranosyl)-N-octadecyldodecanoylamide hydroacetate ).,PMID:7551218,Samantha G. Sayers,BAY R1005|N-( 2-Deoxy-2-L-leucylamino-β-D-glucopyranosyl)-N-octadecyldodecanoylamide hydroacetate,,,,,,,,,
VO:0001288,Avridine vaccine adjuvant,synthetic vaccine adjuvant,"A synthetic vaccine adjuvant that is N, N-dioctadecyl-N′, N′-bis( 2-hydroxyethyl) propanediamine (Avridine).",PMID:7551218,Samantha G. Sayers,"Avridine|CP20,96|N, N-dioctadecyl-N′, N′-bis( 2-hydroxyethyl) propanediamine",,,,,,,,,
VO:0001289,calcium phosphate gel vaccine adjuvant,calcium phosphate vaccine adjuvant,A calcium phosphate vaccine adjuvant that is a gel prepared by precipitating soluable calcium and phosphate salts.,PMID:7551218,Samantha G. Sayers,calcium phosphate gel,,,,,,,,,
VO:0001290,cholera toxin A1-subunit-ProteinA D-fragment fusion protein,microbial derivative vaccine adjuvant,A microbial derivative vaccine adjuvant composed of the CTA1-DD fusion protein.,PMID:7551218,Samantha G. Sayers,CTA1-DD gene fusion protein,,,,,,,,,
VO:0001291,DOC/Alum Complex vaccine adjuvant,mineral salt vaccine adjuvant,A mineral salt vaccine adjuvant that is composed of Deoxycholic acid sodium salt (DOC) complexed with aluminum hydroxide.,PMID:7551218,Samantha G. Sayers,DOC/Alum Complex,,,,,,,,,
VO:0001292,gamma Inulin vaccine adjuvant,carbohydrate vaccine adjuvant,"A carbohydrate adjuvant that is a highly specific activator of the alternative pathway of complement in vitro and in vivo, and is composed of linear (unbranched) b-D-(2-1) polyfructofuranosyl-a-D-glucose.",PMID:3265692|PMID:7551218,Samantha G. Sayers,,,,,,,,,,
VO:0001293,Gerbu vaccine adjuvant,combination vaccine adjuvant,"A combination vaccine adjuvant that is comprised of a mixture of GMDP, DDA, and Zinc L-proline salt complex (ZnPro8).",PMID:7551218|PMID:15953835,Samantha G. Sayers,,,,,,,,,,
VO:0001294,GM-CSF vaccine adjuvant,cytokine vaccine adjuvant,A cytokine vaccine adjuvant that includes GM-CSF.,,Oliver He|Samantha G. Sayers,,,,,,,,,,
VO:0001295,GMDP vaccine adjuvant,synthetic vaccine adjuvant,"A synthetic vaccine adjuvant containing GMDP, a higly effective primary adjuvant.",PMID:7551218,Samantha G. Sayers,GMDP|N-acetylglucosaminyl-(b1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine,,,,,,,,,
VO:0001296,recombinant hIFN-gamma/Interferon-g vaccine adjuvant,IFN-gamma vaccine adjuvant,An IFN-gamma vaccine adjuvant that is composed of recombinant hIFN-gamma.,,Oliver He|Samantha G. Sayers,,,,,,,,,,
VO:0001297,interleukin-1b vaccine adjuvant,cytokine vaccine adjuvant,A cytokine vaccine adjuvant that includes IL-1b.,,Oliver He|Samantha G. Sayers,,,,,,,,,,
VO:0001298,interleukin-2 vaccine adjuvant,cytokine vaccine adjuvant,A cytokine vaccine adjuvant that includes IL-2.,,Oliver He|Samantha G. Sayers,IL-2 vaccine adjuvant,,,,,,,,,
VO:0001299,interleukin-7 vaccine adjuvant,cytokine vaccine adjuvant,A cytokine vaccine adjuvant that includes IL-7.,,Oliver He|Samantha G. Sayers,IL-7 vaccine adjuvant,,,,,,,,,
VO:0001300,Loxoribine vaccine adjuvant,synthetic vaccine adjuvant,"A synthetic vaccine adjuvant that includes loxoribine which is a guanosine analog derivatized at position N7 and C8, and activates TLR-7.",PMID:7551218,Samantha G. Sayers,7-allyl-8-oxoguanosine|Loxoribine,,,,,,,,,
VO:0001301,MF59 vaccine adjuvant,emulsion vaccine adjuvant,An emulsion vaccine adjuvant consisting of an oil (squalene)-in-water nano emulsion.,PMID:20488726,Samantha G. Sayers,MF59,,,,,,,,,
VO:0001302,MTP-PE Liposomes vaccine adjuvant,liposome-based vaccine adjuvant,"A liposome-based vaccine adjuvant that consists of liposomes containing  the synthetic lipophilic analog of muramyl dipeptide, muramyl tripeptide phosphatidylethanolamine (MTP-PE).",PMID:1431559,Samantha G. Sayers,MTP-PE|MTP-PE Liposomes,,,,,,,,,
VO:0001303,Murametide vaccine adjuvant,synthetic vaccine adjuvant,A synthetic vaccine adjuvant made of murametide that has adjuvant activity similar to MDP.,PMID:7551218,Samantha G. Sayers,Murametide|Nac-Mur-L-Ala-D-Gln-OCH3,,,,,,,,,
VO:0001304,Murapalmitine vaccine adjuvant,synthetic vaccine adjuvant,A synthetic vaccine adjuvant called murapalmitine.,PMID:7551218,Samantha G. Sayers,Murapalmitine|Nac-Mur-L-Thr-D-isoGIn-sn-glyceroI dipalmitoyl,,,,,,,,,
VO:0001305,D-Murapalmitine vaccine adjuvant,synthetic vaccine adjuvant,A synthetic vaccine adjuvant that includes an MDP analog called D-Murapalmitine.,PMID:7551218,Samantha G. Sayers,D-Murapalmitine|Nac-Mur-D-Ala-D-isoGln-sn-glycerol dipalmitoyl,,,,,,,,,
VO:0001306,NAGO vaccine adjuvant,synthetic vaccine adjuvant,A synthetic vaccine adjuvant that is composed of neuraminidase-galactose oxidase (NAGO) a mixture of mixture of the two enzymes-neuraminidase and galactose oxidase.,PMID:7551218,Samantha G. Sayers,NAGO|Neuraminidase-galactose oxidase,,,,,,,,,
VO:0001307,non-ionic surfactant vesicles vaccine adjuvant,synthetic vaccine adjuvant,"A synthetic vaccine adjuvant consisting of multi-lamellar vesicles comprising a mixture of non-ionic surfactant (e.g., 1-monopalmitoyl-rac-glycerol), cholesterol and dicetyl phosphate used as a primary vaccine adjuvant for entrapped antigen.",PMID:7551218,Samantha G. Sayers,NISV|non-ionic surfactant vesicles,,,,,,,,,
VO:0001308,PMMA vaccine adjuvant,synthetic vaccine adjuvant,A synthetic vaccine adjuvant made from the emulsion polymerization of methyl methacrylate.,PMID:7551218,Samantha G. Sayers,PMMA|Polymethyl methacrylate,,,,,,,,,
VO:0001309,protein cochleates vaccine adjuvant,synthetic vaccine adjuvant,A synthetic vaccine adjuvant synthesized from stable protein phospholipid-calcium precipitates.,PMID:7551218,Samantha G. Sayers,protein cochleates,,,,,,,,,
VO:0001310,QS-21 vaccine adjuvant,saponin vaccine adjuvant,"A saponin vaccine adjuvant that is composed of extracts from the bark of the Quillaja saponaria Molina tree. Specifically, it is an acylated 3, 28-bisdesmodic triterpene glycosides (1,3) or ‚Äúsaponin‚Äù with a molecular formula of C92O46H148 and molecular weight of 1990 Da. QS-21 is one of the active fractions of the bark of Chilean tree, Quillaja saponaria, purified using a reverse-phase chromatography (RP-HPLC).",PMID:7551218|PMID:27213168,Samantha G. Sayers|Randi Vita|Oliver He,QS-21|Stimulon™ QS-21 Adjuvant,,,,,,,,,
VO:0001311,Rehydragel HPA vaccine adjuvant,aluminum vaccine adjuvant,An aluminum vaccine adjuvant that is a synthetic oxyhydroxide of aluminum (aluminum hydroxide) prepared by acid-base precipitation.,PMID:7551218,Samantha G. Sayers,Rehydragel HPA,,,,,,,,,
VO:0001312,Rehydragel LV vaccine adjuvant,aluminum hydroxide vaccine adjuvant,An aluminum hydroxide vaccine adjuvant that is a low visosity aluminum hydroxide gel.,PMID:7551218,Samantha G. Sayers,Rehydragel LV,,,,,,,,,
VO:0001313,Sclavo peptide vaccine adjuvant,cytokine vaccine adjuvant,A cytokine vaccine adjuvant that contains the 163-171 peptide of IL-1β.,,Oliver He|Samantha G. Sayers,IL-1β 163-171 peptide vaccine adjuvant|Sclavo peptide,,,,,,,,,
VO:0001314,Specol vaccine adjuvant,emulsion vaccine adjuvant,An emulsion vaccine adjuvant that is a water-in-oil emulsion that is used as an adjuvant and has immunostimulating properties similar to Freund's complete adjuvant (FCA).,PMID:1439130,Samantha G. Sayers,Specol,,,,,,,,,
VO:0001315,SPT (Antigen Formulation),emulsion vaccine adjuvant,"An emulsion vaccine adjuvant that is an emulsion of squalane (5%), Tween 80( 0.2%), Pluronic L121( 1.25%), phosphate-buffered saline pH 7.4, and antigen.",PMID:7551218,Samantha G. Sayers,,,,,,,,,,
VO:0001316,stearyl tyrosine vaccine adjuvant,synthetic vaccine adjuvant,"A synthetic vaccine adjuvant stearyl tyrosine is considered an ""organic equivelant"" of aluminum hydroxide.",PMID:7551218,Samantha G. Sayers,stearyl tyrosine,,,,,,,,,
VO:0001317,Theramide vaccine adjuvant,synthetic vaccine adjuvant,A synthetic vaccine adjuvant called Theramide that is composed of N-acetylglucosaminyl-N-acetylinuramyl-L-Ala-D-isoGlu-L-Ala-dipalmitoxy propylamide (DTP-DPP).,PMID:7551218,Samantha G. Sayers,Theramide,,,,,,,,,
VO:0001318,CRL1005 vaccine adjuvant,synthetic vaccine adjuvant,"A synthetic vaccine adjuvant that is a copolymer (CRL1005), based on a 12 kDa polyoxypropylene (POP) core with 5% POE.",PMID:10717336,Samantha G. Sayers,CRL1005,,,,,,,,,
VO:0001319,nanoemulsion vaccine adjuvant,emulsion vaccine adjuvant,An emulsion vaccine adjuvant and is made from non-toxic lipid droplets a few hundred nanometers in diameter and made from surfactants approved for human consumption and common food substances that are 'Generally Recognized as Safe' (GRAS) by the FDA.,http://nano.med.umich.edu/platforms/Nanoemulsions.html,Samantha G. Sayers,,,,,,,,,,
VO:0001320,AS03 vaccine adjuvant,emulsion vaccine adjuvant,"An emusion vaccine adjuvant that contains α-tocopherol and squalene, two biodegradable polyprenyls, in an oil-in-water emulsion.",PMID:21256188,Samantha G. Sayers,AS03,,,,,,,,,
VO:0001321,LTR192G vaccine adjuvant,E. coli LT toxin derived vaccine adjuvant,An E. coli LT toxin derived vaccine adjuvant that is a mutant form of E.coli heat-labile toxin.,PMID:11803061,Samantha G. Sayers,LTR192G,,,,,,,,,
VO:0001322,E. coli heat-labile toxin vaccine adjuvant,microbial derivative vaccine adjuvant,A microbial derivative vaccine adjuvant containing E. coli heat-labile toxin.,PMID:7551218,Samantha G. Sayers,"E. coli heat-labile toxin, LT|LT Oral Adjuvant|LT-OA",,,,,,,,,
VO:0001323,amorphous aluminum hydroxyphosphate sulfate adjuvant,aluminum vaccine adjuvant,An aluminum vaccine adjuvant that is a a proprietary aluminum hydroxyphosphate sulfate formulation that is both physically and functionally distinct from traditional aluminum phosphate and aluminum hydroxide adjuvants.,PMID:17581283,Samantha G. Sayers,AAHSA|Merck Aluminum Adjuvant,,,,,,,,,
VO:0001324,Matrix-S vaccine adjuvant,tensoactive compound vaccine adjuvant,,,,Matrix-S,,,,,,,,,
VO:0001328,imiquimod vaccine adjuvant,synthetic vaccine adjuvant,A synthetic vaccine adjuvant contiaing imiquimod a imidazoquinoline.,PMID:7551218|PMID:18566444,Samantha G. Sayers,"1-(2-methypropyl)-IH-imidazo[4,5-c]quinolin-4-amine|Aldara™|R-837|S26308",,,,,,,,,
VO:0001329,resiquimod vaccine adjuvant,synthetic vaccine adjuvant,"A synthetic vaccine adjuvant, resiquimod is a chemical analog of imiquimod.",PMID:15068862,Samantha G. Sayers,,,,,,,,,,
VO:0001330,AF03 vaccine adjuvant,emulsion vaccine adjuvant,An emulsion vaccine adjuvant containing 2.5% squalene.,PMID:20193791,Samantha G. Sayers,,,,,,,,,,
VO:0001331,Flagellin vaccine adjuvant,microbial derivative vaccine adjuvant,A microbial derivative vaccine adjuvant composed of flagellin from gram-negative bacteria.,PMID:16428759|PMID:21048152,Samantha G. Sayers,FliC,,,,,,,,,
VO:0001332,poly(I:C) vaccine adjuvant,synthetic vaccine adjuvant,"A synthetic vaccine adjuvant containing Poly(I:C), a synthetic double stranded analog of RNA.",WEB: http://en.wikipedia.org/wiki/Polyinosinic:polycytidylic_acid,Samantha G. Sayers,polyriboinosinic-polyribocytidylic acid,,,,,,,,,
VO:0001333,ISCOMATRIX vaccine adjuvant,particulate antigen delivery system,"A particulate antigen delivery system that is a vaccine adjuvant comprising cholesterol, phospholipid and saponin but without antigen.",PMID:19450632,Samantha G. Sayers,,,,ISCOMATRIX is identical to ISCOMs except that it does not contain antigen. Ref: PMID: 17336431.,,,,,,
VO:0001334,Abisco-100 vaccine adjuvant,saponin vaccine adjuvant,A saponin vaccine adjuvant that is made from highly purified saponins.,WEB: http://www.isconova.com/products/abisco-research-reagent/abisco-100.aspx,Samantha G. Sayers|Oliver He,,,,,,,,,,
VO:0001335,albumin-heparin microparticles vaccine adjuvant,particulate antigen delivery system,A particulate antigen delivery system  that is albumin-heparin microparticles vaccine adjuvant that is prepared from albumin and heparin stabilized by cross-linking reaction with EDC.,PMID:16734558,Samantha G. Sayers,,,,,,,,,,
VO:0001336,AS-2 vaccine adjuvant,combination vaccine adjuvant,"A combination vaccine adjuvant and is based on the combination of Monophosphoryl Lipid A(MPL), QS21 (a purified fraction of Saponin extracted from Quillarja Saponaria), and a proprietary oil in water emulsion.",http://www.pasteur.fr/applications/euroconf/vaccins/vaccins-abs.html,Samantha G. Sayers,,,,,,,,,,
VO:0001337,B7-2 vaccine adjuvant,cytokine vaccine adjuvant,A cytokine vaccine adjuvant that includes B7-2.,,Oliver He|Samantha G. Sayers,,,,,,,,,,
VO:0001338,Bupivacaine vaccine adjuvant,synthetic vaccine adjuvant,"A synthetic vaccine adjuvant that is a local anaesthetic drug belonging to the amino amide group, and is used as a vaccine adjuvant in DNA vaccines.",PMID:15246629|WEB: http://en.wikipedia.org/wiki/Bupivacaine,Samantha G. Sayers,,,,,,,,,,
VO:0001339,cationic liposome-DNA complex JVRS-100 vaccin adjuvant,liposome-based vaccine adjuvant,A liposome-based vaccine adjuvant that is composed of virus sized liposomes that contain a DNA plasmid.,PMID:19285425,Samantha G. Sayers,cationic liposome-DNA complex JVRS-100,,,,,,,,,
VO:0001340,DHEA vaccine adjuvant,synthetic vaccine adjuvant,"A synthetic vaccine adjuvant that is DHEA, which is relatively stable and can be directly incorporated into vaccine formulations.",PMID:7551218,Samantha G. Sayers,5-androsten-3Œ≤-ol-17-one|DHA|Dehydroepiandrosterone|androstenolone|prasterone|transdehydroandrosterone,,,,,,,,,
VO:0001341,DL-PGL (Polyester poly (DL-lactide-co-glycolide)) vaccine adjuvant,synthetic vaccine adjuvant,"A synthetic vaccine adjuvant that is PLGA, which has been used in the controlled delivery of peptide drugs.",PMID:15560948,Samantha G. Sayers,PLGA|PLGA microspheres|Polyester poly (DL-lactide-co-glycolide),,,,,,,,,
VO:0001342,IL-15 vaccine adjuvant,cytokine vaccine adjuvant,A cytokine vaccine adjuvant that uses the adjuvant effect of cytokine IL-15.,,Oliver He|Samantha G. Sayers,,,,,,,,,,
VO:0001343,immunoliposomes containing antibodies to costimulatory molecules,liposome-based vaccine adjuvant,A liposome-based vaccine adjuvant which is prepared from dehydration-rehydration vesicles (DRVs).,PMID:7551218,Samantha G. Sayers,,,,,,,,,,
VO:0001344,LTK72 vaccine adjuvant,E. coli LT toxin derived vaccine adjuvant,An E. coli LT toxin derived vaccine adjuvant that is a mutant form of heat-labile Escherichia coli enterotoxin (LT) that contains a substitution Ala → Arg in position 72 of the A subunit.,PMID:9529328,Samantha G. Sayers,,,,,,,,,,
VO:0001345,MPL-SE vaccine adjuvant,microbial derivative vaccine adjuvant,A microbial derivative vaccine adjuvant containing MPL and squalene.,PMID:12213399,Samantha G. Sayers,,,,,,,,,,
VO:0001347,non-toxic mutant E112K of Cholera Toxin mCT-E112K vaccine adjuvant,cholera toxin derived vaccine adjuvant,"A microbial derived vaccine adjuvant made of E112K mC,  a mutated CT created by substituting a single amino acid in the ADP-ribosyltransferase active centre, glutamate to lysine at position 112.",PMID:11251876,Samantha G. Sayers,mCT|non-toxic mutant E112K of Cholera Toxin mCT-E112K,,,,,,,,,
VO:0001348,cholera toxin derived vaccine adjuvant,microbial derivative vaccine adjuvant,A microbial derivative vaccine adjuvant that is derived from cholera toxin.,,Oliver He|Samantha G. Sayers,,,,,,,,,,
VO:0001349,SAF-1 vaccine adjuvant,combination vaccine adjuvant,"A combination vaccine adjuvant that is composed of threonyl-MDP (0.05-1%) in an emulsion vehicle [5% squalane, 2.5% Pluronic® L121, 0.2% Polysorbate 80 and phosphate buffered saline (pH 7.4)].",PMID:7551218,Samantha G. Sayers,,,,,,,,,,
VO:0001350,"Sendai Proteoliposomes, Sendai-containing Lipid Matrices",liposome-based vaccine adjuvant,A liposome-based vaccine adjuvant that includes the glycoproteins of Sendai virus.,PMID:7551218,Samantha G. Sayers,,,,,,,,,,
VO:0001351,threonyl muramyl dipeptide (TMDP) vaccine adjuvant,synthetic vaccine adjuvant,A synthetic vaccine adjuvant that is threonyl muramyl dipeptide (TMDP).,PMID:7551218,Samantha G. Sayers,N-acetyl muramyl-L-threonyl-D-isoglutamine|Termurtide™|[thr1 ]-MDP,,,,,,,,,
VO:0001352,ty particles vaccine adjuvant,microbial derivative vaccine adjuvant,A microbial derivative vaccine adjuvant made of virus like particles (VLPS) containing the yeast retrotransposon Ty which has the amino acids 1-381 of the pI protein encoded.,PMID:7551218,Samantha G. Sayers,Ty-VLPs,,,,,,,,,
VO:0001353,cytokine vaccine adjuvant,vaccine adjuvant,A vaccine adjuvant that contains active cytokine compound.,,Oliver He|Samantha G. Sayers,,,,,,,,,,
VO:0001354,combination vaccine adjuvant,vaccine adjuvant,A vaccine adjuvant that is composed of differnt compounds under more than one category.,,Oliver He|Samantha G. Sayers,,,,,,,,,,
VO:0001355,emulsion vaccine adjuvant,vaccine adjuvant,,,,,,,,,,,,,
VO:0001356,particulate antigen delivery system,vaccine adjuvant,A vaccine adjuvant that serves as a particulate antigen delivery system.,,Oliver He|Samantha G. Sayers,,,,,,,,,,
VO:0001357,synthetic vaccine adjuvant,vaccine adjuvant,A vaccine adjuvant that contains synthetic material.,,Oliver He|Samantha G. Sayers|Philip Huang,,,,,,,,,,
VO:0001358,tensoactive compound vaccine adjuvant,vaccine adjuvant,"A vaccine adjuvant that includes tensioactive material. Tensioactive materials, surfactants or active surface agents are chemical substances with a polar-non polar structure. These substances have a tendency to locate themselves at the surface creating an adsorbed monomolecular layer on the interface.",WEB: http://www.citt.ufl.edu/team/sepulveda/html/en_tensioactivos.htm,Oliver He|Samantha G. Sayers,tensioactive compound vaccine adjuvant,,,,,,,,,
VO:0001359,carbohydrate vaccine adjuvant,vaccine adjuvant,A vaccine adjuvant that is primarily composed of carbohydrates.,,Oliver He|Samantha G. Sayers,,,,,,,,,,
VO:0001360,IFN-gamma vaccine adjuvant,cytokine vaccine adjuvant,A cytokine vaccine adjuvant that includes IFN-gamma.,,Oliver He|Samantha G. Sayers,,,,,,,,,,
VO:0003154,ISS 1018 CpG ODN vaccine adjuvant,CpG DNA vaccine adjuvant,"A CpG DNA vaccine adjuvant that is a short, synthetic, unmethylated CpG oligodeoxynucleotide (CpG ODN) with immunostimulatory activity.",https://www.cancer.gov/publications/dictionaries/cancer-drug/def/iss-1018-cpg-oligodeoxynucleotide|https://www.drugbank.ca/drugs/DB05463,Oliver He|Kallan Roan,ISS 1018 CpG ODN|ISS 1018 CpG oligodeoxynucleotide|ISS-1018,DrugBank Accession number: DB05463,,"ISS 1018 is a short, synthetic, unmethylated CpG oligodeoxynucleotide (CpG ODN) with immunostimulatory activity. ISS 1018 signals through Toll-like receptor 9 (TLR9) to induce the production of immunoglobulin by B cells and interferon (IFN) -alpha, IFN-beta, interleukin-12 (IL-12), and tumor necrosis factor - alpha (TNF-alpha) by plasmacytoid dendritic cells (pDC). ISS 1018 CpG ODN promotes antigen presentation and co-stimulatory molecule expression. ISS 1018 is currently being investigated in combination with HBsAg vaccine as a prophylactic treatment for to prevent Hepatitis B in adults. It is also being investigated in combination with rituximab for treatment of b-cell or non-hodgkin's lymphoma.",,,,,,
VO:0005206,Matrix-M vaccine adjuvant,saponin vaccine adjuvant,"A saponin vaccine adjuvant comprised of 40 nm nanoparticles composed of Quillaja saponins, cholesterol and phospholipid.",PMID:22844480,Philip Huang,,,,,,,,,,
VO:0005207,Advax vaccine adjuvant,carbohydrate vaccine adjuvant,A carbohydrate vaccine adjuvant derived from delta inulin,PMID:22728225|https://vac.niaid.nih.gov/view?id=37|https://www.ncbi.nlm.nih.gov/pubmed/?term=10000000|https://www.ncbi.nlm.nih.gov/pubmed/?term=12|https://www.ncbi.nlm.nih.gov/pubmed/?term=15479440|https://www.ncbi.nlm.nih.gov/pubmed/?term=20130134|https://www.ncbi.nlm.nih.gov/pubmed/?term=21147758|https://www.ncbi.nlm.nih.gov/pubmed/?term=21169215|https://www.ncbi.nlm.nih.gov/pubmed/?term=21736913|https://www.ncbi.nlm.nih.gov/pubmed/?term=22717330|https://www.ncbi.nlm.nih.gov/pubmed/?term=22728225|https://www.ncbi.nlm.nih.gov/pubmed/?term=23306367|https://www.ncbi.nlm.nih.gov/pubmed/?term=23388724|https://www.ncbi.nlm.nih.gov/pubmed/?term=23864620|https://www.ncbi.nlm.nih.gov/pubmed/?term=24342245|https://www.ncbi.nlm.nih.gov/pubmed/?term=24958701|https://www.ncbi.nlm.nih.gov/pubmed/?term=25267153|https://www.ncbi.nlm.nih.gov/pubmed/?term=25459531|https://www.ncbi.nlm.nih.gov/pubmed/?term=25516480|https://www.ncbi.nlm.nih.gov/pubmed/?term=25520500|https://www.ncbi.nlm.nih.gov/pubmed/?term=25659269|https://www.ncbi.nlm.nih.gov/pubmed/?term=26031451|https://www.ncbi.nlm.nih.gov/pubmed/?term=26177480|https://www.ncbi.nlm.nih.gov/pubmed/?term=26232344|https://www.ncbi.nlm.nih.gov/pubmed/?term=27342914|https://www.ncbi.nlm.nih.gov/pubmed/?term=28301280|https://www.ncbi.nlm.nih.gov/pubmed/?term=28602608|https://www.ncbi.nlm.nih.gov/pubmed/?term=28676380|https://www.ncbi.nlm.nih.gov/pubmed/?term=28758637|https://www.ncbi.nlm.nih.gov/pubmed/?term=30218687|https://www.ncbi.nlm.nih.gov/pubmed/?term=30312742|https://www.ncbi.nlm.nih.gov/pubmed/?term=30322015|https://www.ncbi.nlm.nih.gov/pubmed/?term=30832356|https://www.ncbi.nlm.nih.gov/pubmed/?term=31009889|https://www.ncbi.nlm.nih.gov/pubmed/?term=31300280|https://www.ncbi.nlm.nih.gov/pubmed/?term=33542494|https://www.ncbi.nlm.nih.gov/pubmed/?term=33883559,Nikolai Petrovsky|Wolfgang Leitner|Philip Huang|Oliver He,,,,"Chemical Nature: Carbohydrate
Mechanism of Action: Complement, Dendritic cells (unknown receptor), Other, Unknown
Immune profile induced: mixed Th1/Th2
By routes: IM, IN, IP, SQ, inhalation,
Point of Contact: Nikolai Petrovsky, Vaxine
https://www.ncbi.nlm.nih.gov/pubmed/?term=31009889
https://www.ncbi.nlm.nih.gov/pubmed/?term=25520500
https://www.ncbi.nlm.nih.gov/pubmed/?term=28758637
https://www.ncbi.nlm.nih.gov/pubmed/?term=23864620
https://www.ncbi.nlm.nih.gov/pubmed/?term=24342245
https://www.ncbi.nlm.nih.gov/pubmed/?term=23306367
https://www.ncbi.nlm.nih.gov/pubmed/?term=21147758
https://www.ncbi.nlm.nih.gov/pubmed/?term=15479440
https://www.ncbi.nlm.nih.gov/pubmed/?term=26031451
https://www.ncbi.nlm.nih.gov/pubmed/?term=25659269
https://www.ncbi.nlm.nih.gov/pubmed/?term=33883559
https://www.ncbi.nlm.nih.gov/pubmed/?term=30312742
https://www.ncbi.nlm.nih.gov/pubmed/?term=21736913
https://www.ncbi.nlm.nih.gov/pubmed/?term=30218687
https://www.ncbi.nlm.nih.gov/pubmed/?term=25459531
https://www.ncbi.nlm.nih.gov/pubmed/?term=24958701
https://www.ncbi.nlm.nih.gov/pubmed/?term=25516480
https://www.ncbi.nlm.nih.gov/pubmed/?term=20130134
https://www.ncbi.nlm.nih.gov/pubmed/?term=23388724
https://www.ncbi.nlm.nih.gov/pubmed/?term=21169215
https://www.ncbi.nlm.nih.gov/pubmed/?term=30832356
https://www.ncbi.nlm.nih.gov/pubmed/?term=30322015
https://www.ncbi.nlm.nih.gov/pubmed/?term=28602608
https://www.ncbi.nlm.nih.gov/pubmed/?term=28676380
https://www.ncbi.nlm.nih.gov/pubmed/?term=33542494
https://www.ncbi.nlm.nih.gov/pubmed/?term=26232344
https://www.ncbi.nlm.nih.gov/pubmed/?term=22728225
https://www.ncbi.nlm.nih.gov/pubmed/?term=22728225
https://www.ncbi.nlm.nih.gov/pubmed/?term=25267153
https://www.ncbi.nlm.nih.gov/pubmed/?term=31300280
https://www.ncbi.nlm.nih.gov/pubmed/?term=28301280
https://www.ncbi.nlm.nih.gov/pubmed/?term=22717330
https://www.ncbi.nlm.nih.gov/pubmed/?term=26177480
https://www.ncbi.nlm.nih.gov/pubmed/?term=10000000
https://www.ncbi.nlm.nih.gov/pubmed/?term=27342914
https://www.ncbi.nlm.nih.gov/pubmed/?term=12",37,,,,Th1/Th2 mixed immune profile,
VO:0005270,1V270 vaccine adjuvant,vaccine adjuvant,"A vaccine adjuvant that includes IV270, which is a low–molecular weight TLR7 agonist conjugated to a phospholipid and is a highly potent and stable immune activator.",PMID:25568203|PMID:28724768|PMID:32636840/|https://vac.niaid.nih.gov/view?id=6,Dennis Carson|Wolfgang Leitner|Oliver He,1V270,,,"Chemical Nature: Small molecule
Receptor: TLR7
Mechanism of Action: Activation of innate immune pathways
Immune profile induced: Th1-biased
Other Features/Characteristics: (1) Induces mucosal immunity, (2) Induces CD8 T cells, (3) Induces epitope spreading, (4) Provides innate protection, (5) Promotes antibody affinity maturation, (6) Promotes antibody epitope spreading By routes: intramuscular and intranasal.
Point of Contact: Dennis Carson, UCSD",6,,,TLR7 receptor role,Th1-biased immune profile,
VO:0005271,2B182C vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=7|https://www.ncbi.nlm.nih.gov/pubmed/?term=25568203|https://www.ncbi.nlm.nih.gov/pubmed/?term=28724768|https://www.ncbi.nlm.nih.gov/pubmed/?term=32636840,Dennis Carson|Wolfgang Leitner|Amogh Madireddi|Oliver He,2B182C,,,"Chemical Nature: Small molecule
Receptor: TLR4
Mechanism of Action: Innate immune activation
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: (1) Induces mucosal immunity, (2) Anti-inflammatory, (3) Promotes antibody epitope spreading. By routes: intramuscular and intranasal.
Point of Contact: Dennis Carson, UCSD",7,,,TLR4 receptor role,Th1/Th2 mixed immune profile,
VO:0005281,2E151 vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=9,Dennis Carson|Wolfgang Leitner|Amogh Madireddi|Oliver He,2.00E+151,,,"Chemical Nature: Small molecule
Receptor: Dendritic cells (unknown receptor)
Mechanism of Action: Innate immune activation
Immune profile induced: Th1-biased
Other Features/Characteristics: Other. Specify: Co-adjuvant for TLR4 ligands
Point of Contact: Dennis Carson, UCSD",9,,,,Th1-biased immune profile,
VO:0005282,UM-1098 vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=27,Kendal Ryter|Wolfgang Leitner|Amogh Madireddi|Oliver He,UM-1098,,,"Chemical Nature: Small molecule
Receptor: CLR (Dectin, Mincle)
Mechanism of Action: None/Unknown
Immune profile induced: Th17-component
Other Features/Characteristics: None
Point of Contact: Kendal Ryter, U. Montana & Inimmune",,,,,Th17 immune profile,
VO:0005283,TQL-1055 vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=36,Melissa Malhame|Wolfgang Leitner|Amogh Madireddi|Oliver He,TQL-1055,,,"Chemical Nature: Small molecule and Synthetic derivative of natural compound
Receptor: Unknown and NLRP3
Mechanism of Action: Presumably the same as QS-21 in the absence of dose-limiting toxicity
Immune profile induced: Th1-biased
Other Features/Characteristics: None
Point of Contact: Melissa Malhame, Adjuvance Technologies",,,,,Th1-biased immune profile,
VO:0005284,NanoVax/NE01 vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=22|https://www.ncbi.nlm.nih.gov/pubmed/?term=31495593|https://www.ncbi.nlm.nih.gov/pubmed/?term=31515143,Ali Fattom|Wolfgang Leitner|Amogh Madireddi|Oliver He,NanoVax/NE01,,,"Chemical Nature: Emulsion
Receptor: TLR2 and TLR4
Mechanism of Action: Activation of mucosal and systemic immunity
Immune profile induced: Th1/Th17
Other Features/Characteristics: Promotes antibody affinity maturation
Point of Contact: Ali Fattom, BlueWillow Biologics",,,,TLR2 receptor role|TLR4 receptor role,Th1/Th17 mixed immune profile,
VO:0005285,MiT4 vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=16,Darrick Carter|Wolfgang Leitner|Amogh Madireddi|Oliver He,MiT4,,,"Chemical Nature: Other
Receptor: TLR4
Mechanism of Action: TLR4 agonist
Immune profile induced: Th1-biased
Other Features/Characteristics: None/Unknown
Point of Contact: Darrick Carter, PAI Life Sciences",,,,TLR4 receptor role,Th1-biased immune profile,
VO:0005286,Mannadjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=14,Ivan Zanoni|Wolfgang Leitner|Amogh Madireddi|Oliver He,,,,"Chemical Nature: (1) Natural compound, (2) Carbohydrate, (3) Combination adjuvant
Receptor: CLR (Dectin, Mincle) and NAIP
Mechanism of Action: Activation of Dectin-2-expressing innate immune cells; dual targeting of injection site and draining lymph node.
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: Promotes antibody epitope spreading
Point of Contact: Ivan Zanoni, Boston Children's Hospital",,,,,Th1/Th2 mixed immune profile,
VO:0005287,LiT4 vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=20,Darrick Carter|Wolfgang Leitner|Amogh Madireddi|Oliver He,LiT4,,,"Chemical Nature: Combination Adjuvant
Receptor: TLR4
Mechanism of Action: TLR4 agonist plus potential inflammasome
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: None/Unknown
Point of Contact: Darrick Carter, PAI Life Sciences",,,,TLR4 receptor role,Th1/Th2 mixed immune profile,
VO:0005288,INI-4001 vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=28,Kendal Ryter|Wolfgang Leitner|Amogh Madireddi|Oliver He,INI-4001,,,"Chemical Nature: Small molecule
Receptor: TLR7 and TLR8
Mechanism of Action: None/Unknown
Immune profile induced: Th1-biased
Other Features/Characteristics: None
Point of Contact: Kendal Ryter, U. Montana & Inimmune",,,,TLR7 receptor role|TLR8 receptor role,Th1-biased immune profile,
VO:0005289,INI-2004 vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=26,Kendal Ryter|Wolfgang Leitner|Amogh Madireddi|Oliver He,INI-2004,,,"Chemical Nature: Small molecule
Receptor: TLR4
Mechanism of Action: None/Unknown
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: None
Point of Contact: Kendal Ryter, U. Montana & Inimmune",,,,TLR4 receptor role,Th1/Th2 mixed immune profile,
VO:0005290,INI-2002 vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=29,Kendal Ryter|Wolfgang Leitner|Amogh Madireddi|Oliver He,INI-2002,,,"Chemical Nature: Small molecule
Receptor: TLR4
Mechanism of Action: None/Unknown
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: None
Point of Contact: Kendal Ryter, U. Montana & Inimmune",,,,TLR4 receptor role,Th1/Th2 mixed immune profile,
VO:0005291,Fos47 vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=5|https://www.ncbi.nlm.nih.gov/pubmed/?term=25568203|https://www.ncbi.nlm.nih.gov/pubmed/?term=28724768|https://www.ncbi.nlm.nih.gov/pubmed/?term=32636840,Dennis Carson|Wolfgang Leitner|Amogh Madireddi|Oliver He,Fos47,,,"Chemical Nature: Small molecule and Combination adjuvant
Receptor: TLR4 and TLR7
Mechanism of Action: Activation of antigen presenting cells and stimulating B cell proliferation
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: (1) Induces mucosal immunity, (2) Induces CD8 T cells, (3) Induces epitope spreading, (4) Provides innate protection, (5) Promotes antibody epitope spreading. By routes: intramuscular and intranasal.
Point of Contact: Dennis Carson, UCSD",,,,TLR4 receptor role|TLR7 receptor role,Th1/Th2 mixed immune profile,
VO:0005292,EmT4 vaccine adjuvant,emulsion vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=17,Darrick Carter|Wolfgang Leitner|Amogh Madireddi|Oliver He,EmT4,,,"Chemical Nature: Emulsion
Receptor: TLR4
Mechanism of Action: Squalene emulsion plus TLR4
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: None
Point of Contact: Darrick Carter, PAI Life Sciences",,,,TLR4 receptor role,Th1/Th2 mixed immune profile,
VO:0005293,Em vaccine adjuvant,emulsion vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=18,Darrick Carter|Wolfgang Leitner|Amogh Madireddi|Oliver He,Em,,,"Chemical Nature: Emulsion
Receptor: Unknown
Mechanism of Action: Squalene emulsion possibly triggering inflammasome or through extracellular ATP
Immune profile induced: None
Other Features/Characteristics: None
Point of Contact: Darrick Carter, PAI Life Sciences",,,,,,
VO:0005294,DDO (Defective viral genome-Derived Oligonucleotide) vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=30|https://www.ncbi.nlm.nih.gov/pubmed/?term=24099876|https://www.ncbi.nlm.nih.gov/pubmed/?term=29861183,Carolina Lopez|Wolfgang Leitner|Amogh Madireddi|Oliver He,DDO|DDO (Defective viral genome-Derived Oligonucleotide)|Defective viral genome-Derived Oligonucleotide,,,"Chemical Nature: (1) Synthetic derivative of natural compound, (2) Nucleic acid
Receptor: TLR3
Mechanism of Action: TLR3, possibly RIG-I - agonist
Immune profile induced: Th1-biased
Other Features/Characteristics: (1) Induces mucosal immunity, (2) Induces CD8 T cells, (3) Provides innate protection. By routes: SQ, IM.
Point of Contact: Carolina Lopez, University of Washington at St Louis",,,,TLR3 receptor role,Th1-biased immune profile,
VO:0005295,CaPNP (CaPtivant)(TM) vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=11|https://www.ncbi.nlm.nih.gov/pubmed/?term=11063495|https://www.ncbi.nlm.nih.gov/pubmed/?term=12204953|https://www.ncbi.nlm.nih.gov/pubmed/?term=28716554|https://www.ncbi.nlm.nih.gov/pubmed/?term=28933657|https://www.ncbi.nlm.nih.gov/pubmed/?term=31591662,Tulin Morcol|Wolfgang Leitner|Amogh Madireddi|Oliver He,CaPNP (CaPtivant)(TM),,,"Chemical Nature: Synthetic derivative of natural compound
Receptor: Unknown
Mechanism of Action: (1) Antigen carrier, (2) Innate immune enhancer/activator
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: (1) Induces mucosal immunity, (2) Induces CD8 T cells, (3) Provides innate protection, (4) Other, (5) Promotes antibody affinity maturation, (6) High stability. By routes: IM, IN, IP, IN, ID, IVag. Specify: Safe for systemic or mucosal administration
Point of Contact: Tulin Morcol, Captivate Pharma",11,,,,Th1/Th2 mixed immune profile,
VO:0005296,BECC470b vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=32|https://www.ncbi.nlm.nih.gov/pubmed/?term=28487429|https://www.ncbi.nlm.nih.gov/pubmed/?term=29861179|https://www.ncbi.nlm.nih.gov/pubmed/?term=33309485,Robert Ernst|Wolfgang Leitner|Amogh Madireddi|Oliver He,BECC470b,,,"Chemical Nature: Small molecule, other
Receptor: TLR4
Mechanism of Action: None
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: Other
Point of Contact: Robert Ernst, University of Maryland - Baltimore",32,,,TLR4 receptor role,Th1/Th2 mixed immune profile,
VO:0005297,BECC438s vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=33,Robert Ernst|Wolfgang Leitner|Amogh Madireddi|Oliver He,BECC438s,,,"Chemical Nature: (1) Synthetic derivative of natural compound, (2) other
Receptor: TLR4
Mechanism of Action: None
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: None
Point of Contact: Robert Ernst, University of Maryland-Baltimore",33,,,TLR4 receptor role,Th1/Th2 mixed immune profile,
VO:0005298,BECC438b vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=31|https://www.ncbi.nlm.nih.gov/pubmed/?term=28487429|https://www.ncbi.nlm.nih.gov/pubmed/?term=29861179|https://www.ncbi.nlm.nih.gov/pubmed/?term=33309485,Robert Ernst|Wolfgang Leitner|Amogh Madireddi|Oliver He,BECC438b,,,"Chemical Nature: Small molecule, other
Receptor: TLR4
Mechanism of Action: None
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: None
Point of Contact: Robert Ernst, University of Maryland Baltimore",31,,,TLR4 receptor role,Th1/Th2 mixed immune profile,
VO:0005299,AlT4 vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=19,Darrick Carter|Wolfgang Leitner|Amogh Madireddi|Oliver He,AlT4,,,"Chemical Nature: Combination adjuvant
Receptor: TLR4
Mechanism of Action: TLR4 and potentially inflammasome
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: None
Point of Contact: Darrick Carter, PAI Life Services",19,,,TLR4 receptor role,Th1/Th2 mixed immune profile,
VO:0005300,AlT3 vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=21,Darrick Carter|Wolfgang Leitner|Amogh Madireddi|Oliver He,AlT3,,,"Chemical Nature: Combination adjuvant
Receptor: TLR3
Mechanism of Action: TLR3 agonist plus potential inflammasome
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: None
Point of Contact: Darrick Carter, PAI Life Services",21,,,TLR3 receptor role,Th1/Th2 mixed immune profile,
VO:0005301,Alhydroxiquim-II vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=12|https://www.ncbi.nlm.nih.gov/pubmed/?term=33521604|https://www.ncbi.nlm.nih.gov/pubmed/?term=33654090,Sunil David|Wolfgang Leitner|Amogh Madireddi|Oliver He,Alhydroxiquim-II,,,"Chemical Nature: Small molecule
Receptor: (1) TLR7, (2) TLR8
Mechanism of Action: TLR7/8 dual agonist - lymph node delivery
Immune profile induced: Th1-biased
Other Features/Characteristics: Promotes antibody affinity maturation
Point of Contact: Sunil David, Virovax",12,,,TLR7 receptor role|TLR8 receptor role,Th1-biased immune profile,
VO:0005302,Adjuplex+GLA vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=15|https://www.ncbi.nlm.nih.gov/pubmed/?term=32984856|https://www.ncbi.nlm.nih.gov/pubmed/?term=33444400|https://www.ncbi.nlm.nih.gov/pubmed/?term=33767689,Marulasiddappa Suresh|Wolfgang Leitner|Amogh Madireddi|Oliver He,Adjuplex+GLA,,,"Chemical Nature: (1) Synthetic derivative of natural compound, (2) Emulsion, (3) Combination adjuvant, (4) Other
Receptor: TLR4
Mechanism of Action: Adjuplex enhances cross presentation to CD8 T cells and GLA stimulates TLR4 signaling
Immune profile induced: Mixed Th1/Th17
Other Features/Characteristics: None
Point of Contact: Marulasiddappa Suresh, UW Madison",15,,,TLR4 receptor role,Th1/Th17 mixed immune profile,
VO:0005303,2F52 vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=8|https://www.ncbi.nlm.nih.gov/pubmed/?term=29751735,Dennis Carson|Wolfgang Leitner|Amogh Madireddi|Oliver He,2F52,,,"Chemical Nature: Small molecule
Receptor: Dendritic cells (unknown receptor)
Mechanism of Action: Innate immune activation/enhancer
Immune profile induced: Mixed Th1/Th2
Other Features/Characteristics: None
Point of Contact: Dennis Carson, UCSD",8,,,,Th1/Th2 mixed immune profile,
VO:0005324,Advax-CpG55.2 vaccine adjuvant,Advax-CpG vaccine adjuvant,An Advax-CpG vaccine adjuvant that includes an inulin-based polysaccharide (Advax) and a CpG oligodeoxynucleotide CpG55.2.,https://pubmed.ncbi.nlm.nih.gov/32636840/|https://vac.niaid.nih.gov/view?id=38|https://www.ncbi.nlm.nih.gov/pubmed/?term=32849580|https://www.ncbi.nlm.nih.gov/pubmed/?term=33301675|https://www.ncbi.nlm.nih.gov/pubmed/?term=34069575,Nikolai Petrovsky|Wolfgang Leitner|Oliver He,Advax-CpG55.2,,,"Pubmed References:Chemical Nature: (1) combination adjuvant
Mechanism of Action: (1) complement, (2) dendritic cells, (3) other/unknown, (4) TLR9 Immune profile induced: mixed Th1
Other Features/Characteristics: (1) induces CD8 T cells, (2) provides innate protection, (3) anti-inflammatory, (4) promotes antibody affinity maturation, (5) effective in newborns, (6) high stability
By routes: SQ, IM
Point of Contact: Nikolai Petrovsky, Vaxine LTD",38,,,,Th1-biased immune profile,
VO:0005325,VSA-2 vaccine adjuvant,vaccine adjuvant,A vaccine adjuvant that is synthesized by derivatizing a natural Momordica saponin in one step.  VSA-2 is chemically stable. VSA-2 is much less toxic than QS-21.  VSA-2 is more Th1-biased than QS-21. Momordica saponins are isolated from widely available and sustainable sources.,https://vac.niaid.nih.gov/view?id=42|https://www.ncbi.nlm.nih.gov/pubmed/?term=32101001,Pengfei Wang|Wolfgang Leitner|Oliver He,VSA-2,,,"Pubmed References:
Chemical Nature: (1) Synthetic derivative of natural compound
Mechanism of Action: unknown
Immune profile induced: mixed Th1/Th2
Other Features/Characteristics: (1) synthetic saponin with lower toxicity and higher stability than QS21
By routes: SQ
Point of Contact: Pengfei Wang, University of Alabama
https://www.ncbi.nlm.nih.gov/pubmed/?term=32101001",42,,,,Th1/Th2 mixed immune profile,
VO:0005326,VSA-1 vaccine adjuvant,vaccine adjuvant,A vaccine adjuvant that is prepared by derivatizing a natural Momordica saponin in one chemical step. VSA-1 is chemically more stable than QS-21. VSA-1 is much less toxic than QS-21. The Momordica saponins are from sustainable sources and widely available.,https://vac.niaid.nih.gov/view?id=41|https://www.ncbi.nlm.nih.gov/pubmed/?term=31657920,Pengfei Wang|Wolfgang Leitner|Oliver He,VSA-1,,,"Pubmed References:
Chemical Nature: (1) Synthetic derivative of natural compound
Mechanism of Action: unknown
Immune profile induced: mixed Th1/Th2
Other Features/Characteristics: (1) synthetic saponin with lower toxicity and higher stability than QS21
By routes: SQ
Point of Contact: Pengfei Wang, University of Alabama
https://www.ncbi.nlm.nih.gov/pubmed/?term=31657920",41,,,,Th1/Th2 mixed immune profile,
VO:0005327,rOv-ASP-1 vaccine adjuvant,vaccine adjuvant,"A vaccine adjuvant that is a potent adjuvant for antibody and cellular responses to protein, polypeptide and small peptide antigens. rOv-ASP-1 stands for Recombinant Onchocerca volvulus activation-associated secreted protein-1.",https://vac.niaid.nih.gov/view?id=43|https://www.ncbi.nlm.nih.gov/pubmed/?term=1583768|https://www.ncbi.nlm.nih.gov/pubmed/?term=18341617|https://www.ncbi.nlm.nih.gov/pubmed/?term=18675867|https://www.ncbi.nlm.nih.gov/pubmed/?term=22615877|https://www.ncbi.nlm.nih.gov/pubmed/?term=24681229|https://www.ncbi.nlm.nih.gov/pubmed/?term=25736195|https://www.ncbi.nlm.nih.gov/pubmed/?term=26795365|https://www.ncbi.nlm.nih.gov/pubmed/?term=29764680|https://www.ncbi.nlm.nih.gov/pubmed/?term=32471056,Sara Lustigman|Wolfgang Leitner|Oliver He,Recombinant O. volvulus activation-associated secreted protein-1|rOv-ASP-1,,,"Pubmed References:
Chemical Nature: (1) Protein
Mechanism of Action: unknown
Immune profile induced: Th1
Other Features/Characteristics: (1) Induces CD8 T cells, (2) provides innate protection, (3) promotes antibody affinity maturation.
By routes: IM
Point of Contact: Sara Lustigman, New York Blood Center",43,,,,Th1-biased immune profile,
VO:0005329,dmLT vaccine adjuvant,vaccine adjuvant,A vaccine adjuvant that includes double mutant of heat-labile E. coli toxin (LT) at R192G/L211A or LT(R192G/L211A),https://vac.niaid.nih.gov/view?id=13|https://www.ncbi.nlm.nih.gov/pubmed/?term=19897067|https://www.ncbi.nlm.nih.gov/pubmed/?term=21288994|https://www.ncbi.nlm.nih.gov/pubmed/?term=22202122|https://www.ncbi.nlm.nih.gov/pubmed/?term=23541621|https://www.ncbi.nlm.nih.gov/pubmed/?term=24453241|https://www.ncbi.nlm.nih.gov/pubmed/?term=25111827|https://www.ncbi.nlm.nih.gov/pubmed/?term=25803825|https://www.ncbi.nlm.nih.gov/pubmed/?term=26018536|https://www.ncbi.nlm.nih.gov/pubmed/?term=26305793|https://www.ncbi.nlm.nih.gov/pubmed/?term=26540197|https://www.ncbi.nlm.nih.gov/pubmed/?term=3578125|https://www.ncbi.nlm.nih.gov/pubmed/?term=4927082|https://www.ncbi.nlm.nih.gov/pubmed/?term=5216441|https://www.ncbi.nlm.nih.gov/pubmed/?term=5461379|https://www.ncbi.nlm.nih.gov/pubmed/?term=6803349,Elizabeth Norton|Wolfgang Leitner|Oliver He,dmLT,,,"Chemical Nature: protein
Mechanism of Action: CGM1 ganglioside, cAMP, inflammasome
Immune profile induced: mixed Th1/Th17
Other Features/Characteristics: Induces mucosal immunity (IM, ID, SQ, SL, oral, , transcutaneous), Induces epitope spreading, Promotes antibody affinity maturation, Effective in newborns, promotes antibody epitope spreading
By routes: IM, ID, SL, oral, SQ, IN, IP, intragastric, transcutaneous, transdermal, buccal, intrarectal
Point of Contact: Elizabeth Norton, Tulane University

https://www.ncbi.nlm.nih.gov/pubmed/?term=21288994
https://www.ncbi.nlm.nih.gov/pubmed/?term=6803349
https://www.ncbi.nlm.nih.gov/pubmed/?term=26540197
https://www.ncbi.nlm.nih.gov/pubmed/?term=4927082
https://www.ncbi.nlm.nih.gov/pubmed/?term=26305793
https://www.ncbi.nlm.nih.gov/pubmed/?term=25111827
https://www.ncbi.nlm.nih.gov/pubmed/?term=24453241
https://www.ncbi.nlm.nih.gov/pubmed/?term=22202122
https://www.ncbi.nlm.nih.gov/pubmed/?term=25803825
https://www.ncbi.nlm.nih.gov/pubmed/?term=23541621
https://www.ncbi.nlm.nih.gov/pubmed/?term=26018536
https://www.ncbi.nlm.nih.gov/pubmed/?term=5461379
https://www.ncbi.nlm.nih.gov/pubmed/?term=3578125
https://www.ncbi.nlm.nih.gov/pubmed/?term=5216441
https://www.ncbi.nlm.nih.gov/pubmed/?term=19897067
https://www.ncbi.nlm.nih.gov/pubmed/?term=25944298
https://www.ncbi.nlm.nih.gov/pubmed/?term=6424635
https://www.ncbi.nlm.nih.gov/pubmed/?term=3916310
https://www.ncbi.nlm.nih.gov/pubmed/?term=4826740
https://www.ncbi.nlm.nih.gov/pubmed/?term=2884428
https://www.ncbi.nlm.nih.gov/pubmed/?term=30778066
https://www.ncbi.nlm.nih.gov/pubmed/?term=4893257
https://www.ncbi.nlm.nih.gov/pubmed/?term=28063704
https://www.ncbi.nlm.nih.gov/pubmed/?term=4375349
https://www.ncbi.nlm.nih.gov/pubmed/?term=28792004
https://www.ncbi.nlm.nih.gov/pubmed/?term=25765967
https://www.ncbi.nlm.nih.gov/pubmed/?term=25483682
https://www.ncbi.nlm.nih.gov/pubmed/?term=30638799
https://www.ncbi.nlm.nih.gov/pubmed/?term=21326197
https://www.ncbi.nlm.nih.gov/pubmed/?term=31757774
https://www.ncbi.nlm.nih.gov/pubmed/?term=31427449
https://www.ncbi.nlm.nih.gov/pubmed/?term=6957164
https://www.ncbi.nlm.nih.gov/pubmed/?term=33465933
https://www.ncbi.nlm.nih.gov/pubmed/?term=33465933
https://www.ncbi.nlm.nih.gov/pubmed/?term=33465933
https://www.ncbi.nlm.nih.gov/pubmed/?term=31641151
https://www.ncbi.nlm.nih.gov/pubmed/?term=27133878
https://www.ncbi.nlm.nih.gov/pubmed/?term=27676456
https://www.ncbi.nlm.nih.gov/pubmed/?term=27226279
https://www.ncbi.nlm.nih.gov/pubmed/?term=22406456
https://www.ncbi.nlm.nih.gov/pubmed/?term=30787109
https://www.ncbi.nlm.nih.gov/pubmed/?term=24403527
https://www.ncbi.nlm.nih.gov/pubmed/?term=24403527
https://www.ncbi.nlm.nih.gov/pubmed/?term=30563789
https://www.ncbi.nlm.nih.gov/pubmed/?term=31757774
https://www.ncbi.nlm.nih.gov/pubmed/?term=30473185
https://www.ncbi.nlm.nih.gov/pubmed/?term=30248001
https://www.ncbi.nlm.nih.gov/pubmed/?term=24049109
https://www.ncbi.nlm.nih.gov/pubmed/?term=30797634
https://www.ncbi.nlm.nih.gov/pubmed/?term=31482013
https://www.ncbi.nlm.nih.gov/pubmed/?term=29771685
https://www.ncbi.nlm.nih.gov/pubmed/?term=31757774
https://www.ncbi.nlm.nih.gov/pubmed/?term=25444830

Clinical trials:
https://clinicaltrials.gov/ct2/show/NCT03922061
https://clinicaltrials.gov/ct2/show/NCT04232943
https://clinicaltrials.gov/ct2/show/NCT02531685
https://clinicaltrials.gov/ct2/show/NCT02052934
https://clinicaltrials.gov/ct2/show/NCT02531802
https://clinicaltrials.gov/ct2/show/NCT01147445
https://clinicaltrials.gov/ct2/show/NCT03548064
https://clinicaltrials.gov/ct2/show/ NCT01739231
https://clinicaltrials.gov/ct2/show/NCT03404674
https://clinicaltrials.gov/ct2/show/NCT03729219
https://clinicaltrials.gov/ct2/show/NCT04826094",13,,,,Th1/Th17 mixed immune profile,
VO:0005330,CPDI-01 vaccine adjuvant,vaccine adjuvant,,https://pubmed.ncbi.nlm.nih.gov/10516626/|https://pubmed.ncbi.nlm.nih.gov/10799917/|https://pubmed.ncbi.nlm.nih.gov/12538044/|https://pubmed.ncbi.nlm.nih.gov/19428909/|https://pubmed.ncbi.nlm.nih.gov/21723901/|https://pubmed.ncbi.nlm.nih.gov/9013982/|https://vac.niaid.nih.gov/view?id=39,Joseph Vetro|Wolfgang Leitner|Oliver He,CPDI-01,,,"Chemical Nature: (1) other (Peptide)
Mechanism of Action: C5aR1 on mononuclear phagocytes
Immune profile induced: mixed Th1/Th2
Other Features/Characteristics: (1) Induces CD8 T cells, (2) provides innate protection, (3) promotes antibody affinity maturation.
By routes: SQ, IP, IV.
Point of Contact: Joseph Vetro, University of Nebraska Medical Center
https://pubmed.ncbi.nlm.nih.gov/9013982/, https://pubmed.ncbi.nlm.nih.gov/9013982/, https://pubmed.ncbi.nlm.nih.gov/10516626/, https://pubmed.ncbi.nlm.nih.gov/10799917/, https://pubmed.ncbi.nlm.nih.gov/10799917/, https://pubmed.ncbi.nlm.nih.gov/12538044/, https://pubmed.ncbi.nlm.nih.gov/19428909/, https://pubmed.ncbi.nlm.nih.gov/21723901/",39,,,,Th1/Th2 mixed immune profile,
VO:0005337,UM-3005 vaccine adjuvant,vaccine adjuvant,"A vaccine adjuvant that includes UM-3005, a small molecule TLR7/8 agonist that can stimulate Th1-biased immune profile.",https://vac.niaid.nih.gov/view?id=47|https://www.ncbi.nlm.nih.gov/pubmed/32210973,Helene Bazin-Lee|Wolfgang Leitner|Oliver He|Ani M. Bernardi,UM-3005,,,"Chemical Nature: (1) small molecule
Mechanism of Action: TLR7/8 agonist
Immune profile induced: Th1-biased
Route of immunization: IM
Point of Contact: Helene Bazin-Lee, InImmune",47,,,TLR7 receptor role|TLR8 receptor role,Th1-biased immune profile,
VO:0005353,UM-3004 vaccine adjuvant,vaccine adjuvant,"A vaccine adjuvant that includes UM-3004, a small molecule TLR7/8 agonist that can stimulate Th1-biased immune profile.",https://vac.niaid.nih.gov/view?id=46|https://www.ncbi.nlm.nih.gov/pubmed/32210973,Helene Bazin-Lee|Wolfgang Leitner|Oliver He|Ani M. Bernardi,UM-3004,,,"Chemical Nature: (1) small molecule
Mechanism of Action: TLR7/8 agonist
Immune profile induced: Th1-biased
Route of immunization: IM
Point of Contact: Helene Bazin-Lee, University of Montana",46,,,TLR7 receptor role|TLR8 receptor role,Th1-biased immune profile,
VO:0005354,UM-3003 vaccine adjuvant,vaccine adjuvant,"A vaccine adjuvant that includes UM-3003, a small molecule TLR7/8 agonist that can stimulate Th1-biased immune profile.",https://vac.niaid.nih.gov/view?id=45|https://www.ncbi.nlm.nih.gov/pubmed/32210973,Helene Bazin-Lee|Wolfgang Leitner|Oliver He|Ani M. Bernardi,UM-3003,,,"Chemical Nature: (1) small molecule
Mechanism of Action: TLR7/8 agonist
Immune profile induced: Th1-biased
Route of immunization: IM
Point of Contact: Helene Bazin-Lee, University of Montana",45,,,TLR7 receptor role|TLR8 receptor role,Th1-biased immune profile,
VO:0005355,LTA1 vaccine adjuvant,vaccine adjuvant,"A vaccine adjuvant made from the A subunit of heat-labile (LT) enterotoxin of Enterotoxigenic Escherichia coli (ETEC). This LTA1 adjuvant is able to induce Th1, Th2, and Th17 immune responses.",https://vac.niaid.nih.gov/view?id=44|https://www.ncbi.nlm.nih.gov/pubmed/22526674|https://www.ncbi.nlm.nih.gov/pubmed/26305793|https://www.ncbi.nlm.nih.gov/pubmed/31427449|https://www.ncbi.nlm.nih.gov/pubmed/31641151|https://www.ncbi.nlm.nih.gov/pubmed/31929548|https://www.ncbi.nlm.nih.gov/pubmed/33986280|https://www.ncbi.nlm.nih.gov/pubmed/34516780|https://www.ncbi.nlm.nih.gov/pubmed/6957164,Elizabeth Norton|Wolfgang Leitner|Oliver He|Ani M. Bernardi,LTA1,,,"Chemical Nature: (1) Protein
Mechanism of Action: cAMP, inflammasome induction
Immune profile induced: mixed Th1/Th2/Th17
Other Features/Characteristics: (1) Induces mucosal immunity, (2) Induces epitope spreading, (3) Promotes antibody affinity maturation, (4) Promotes antibody epitope spreading, (5) High stability
Route of immunization: IM, IN, SL, ID, IP
Point of Contact: Elizabeth Norton, Tulane University",44,,,,Th1-biased immune profile|Th17 immune profile|Th2-biased immune profile,
VO:0005356,Adjuvax vaccine adjuvant,carbohydrate vaccine adjuvant,A carbohydrate vaccine adjuvant that is a glucan carbohydrate microcapsules with a β(1-3)/β(1-6) - linked glucan structure to allow targeting of antigens to macrophages or neutrophils through interactions with the β-glucan receptor found uniquely on the surface of these cell types. Adjuvax- ligand complexes are formed by physically entrapping or crosslinking the ligand within the β-glucan.,DOI: 10.1021,Randi Vita|Oliver He,,,,,,,,,,
VO:0005357,Advax-CpG vaccine adjuvant,vaccine adjuvant,A vaccine adjuvant that includes an inulin-based polysaccharide (Advax) and a CpG oligodeoxynucleotide (ODN).,https://pubmed.ncbi.nlm.nih.gov/32636840/|https://www.ncbi.nlm.nih.gov/pubmed/?term=32849580|https://www.ncbi.nlm.nih.gov/pubmed/?term=33301675|https://www.ncbi.nlm.nih.gov/pubmed/?term=34069575,Nikolai Petrovsky|Wolfgang Leitner|Oliver He,Advax-2|Advax-SM|Advax-CpG,,,"Pubmed References:Chemical Nature: (1) combination adjuvant
Mechanism of Action: (1) complement, (2) dendritic cells, (3) other/unknown, (4) TLR9 Immune profile induced: mixed Th1
Other Features/Characteristics: (1) induces CD8 T cells, (2) provides innate protection, (3) anti-inflammatory, (4) promotes antibody affinity maturation, (5) effective in newborns, (6) high stability
By routes: SQ, IM
Point of Contact: Nikolai Petrovsky, Vaxine LTD",,,,,Th1-biased immune profile,
VO:0005358,AS01B vaccine adjuvant,combination vaccine adjuvant,"A combination vaccine adjuvant includes 3-O-desacyl-4’-monophosphoryl lipid A (MPL) from Salmonella minnesota and a saponin molecule (QS-21) purified from plant extract Quillaja saponaria Molina, combined in a liposomal formulation consisting of dioleoyl phosphatidylcholine (DOPC) and cholesterol in phosphate-buffered saline solution.","https://www.fda.gov/media/107538/download#:~:text=The%20AS01B%20adjuvant%20suspension%20is,DOPC)%20and%20cholesterol%20in%20phosphate%2D",Randi Vita|Oliver He,,,,,,,,,,
VO:0005359,AS02A vaccine adjuvant,AS02 vaccine adjuvant,"An AS02 vaccine adjuvant contains 50 ug MPL and 50ug QS21, 250uL of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 mL.",https://clinicaltrials.gov/ct2/show/NCT00308061,,As02a,,,,,,,,,
VO:0005360,chitosan vaccine adjuvant,carbohydrate vaccine adjuvant,A carbohydrate vaccine adjuvant that is aminoglycan consisting of β-(1→4)-linked D-glucosamine residues.,CHEBI:16261|PMID:24346613,Randi Vita|Oliver He,,,,,,,,,,
VO:0005361,Montanide IMS 1313 vaccine adjuvant,Montanide vaccine adjuvant,A Montanide vaccine adjuvant that is a water-dispersed liquid IMS 1313 nanoparticle combined with an immuno-stimulating compound.,https://scialert.net/abstract/?doi=ijps.2018.167.174,Randi Vita|Oliver He,IMS 1313 N VGPR|IMS-1313,,,,,,,,,
VO:0005362,Montanide ISA 206 vaccine adjuvant,Montanide vaccine adjuvant,A water-dispersed liquid nanoparticle combined with an immuno-stimulating compound.,PMID:8961504,Randi Vita|Oliver He,ISA-206,,,,,,,,,
VO:0005363,Montanide ISA 50 vaccine adjuvant,Montanide vaccine adjuvant,"A Montanide vaccine adjuvant that Mannide oleate derivative in a mineral oil solution ( Seppic SA, France).",http://vetarhiv.vef.unizg.hr/papers/74-2/raman.pdf,Randi Vita|Oliver He,ISA-50,,,,,,,,,
VO:0005364,Tomatine vaccine adjuvant,carbohydrate vaccine adjuvant,"A carbohydrate vaccine adjuvant that is tomatidine in which the hydroxy group at position 3 is linked to lycotetraose, a tetrasaccharide composed of two units of D-glucose, one unit of D-xylose, and one unit of D-galactose.",CHEBI:9630,Randi Vita|Oliver He,,,,,,,,,,
VO:0005365,Zymosan vaccine adjuvant,carbohydrate vaccine adjuvant,A carbohydrate vaccine adjuvant that polysaccharide prepared from the cell wall of Saccaromyces cerevisiae (bakers' yeast).,PMID:11380697,Randi Vita|Oliver He,,,,,,,,,,
VO:0005366,XtendIII vaccine adjuvant,emulsion vaccine adjuvant,"An emulsion vaccine adjuvant that is oil-based adjuvant (Adjuvant XtendIII®; Grand Laboratories, Larchwood, IA).",,Randi Vita|Oliver He,,,,,,,,,,
VO:0005367,MPL + TDM vaccine adjuvant,microbial derivative vaccine adjuvant,A microbial derivative vaccine adjuvant that is monophosphoryl lipid A (detoxified endotoxin) from S. minnesota (MPL) and synthetic trehalose dicorynomycolate (TDM) in 2% oil (squalene)-Tween 80-water.,https://www.sigmaaldrich.com/US/en/product/sigma/m6536,Randi Vita|Oliver He,Monophosphoryl-lipid A + Trehalose dicorynomycolate,,,,,,,,,
VO:0005368,Syntex Adjuvant Formulation,muramyl dipeptide vaccine adjuvant,A muramyl dipeptide vaccine adjuvant that muramyl dipeptide derivative (threonyl-MDP) in an oil-in-water (o/w) emulsion vehicle.,https://link.springer.com/protocol/10.1385/1-59259-083-7:229,Randi Vita|Oliver He,SAF,,,,,,,,,
VO:0005369,dibutyl phthalate vaccine adjuvant,vaccine adjuvant,A vaccine adjuvant that diester obtained by the formal condensation of the carboxy groups of phthalic acid with two molecules of butan-1-ol.,CHEBI:34687|PMID:26319029,Randi Vita|Oliver He,DBP,,,,,,,,Th17 immune profile,
VO:0005370,glycerol vaccine adjuvant,vaccine adjuvant,A vaccine adjuvant that includes naturally occurring trivalent alcohol.,https://academic.oup.com/cid/article/45/10/1277/277413,Randi Vita|Oliver He,"glycerine, 1, 2, 3-propanetriol",,,,,,,,Th17 immune profile,
VO:0005371,Pam3Cys vaccine adjuvant,vaccine adjuvant,A vaccine adjuvant includes three palmitic acid groups that are bound in an ester and amide linkage to a cysteine residue.,PMID:24130558,Randi Vita|Oliver He,Tripalmitoyl-S-glyceryl-cysteine,,,,,,,,Th17 immune profile,
VO:0005372,Vaxfectin vaccine adjuvant,vaccine adjuvant,"A vaccine adjuvant that is equimolar mixture of the cationic lipid GAP-DMORIE [(±)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(cis-9-tetradecenyloxy)-1-propanaminium bromide)] and a neutral colipid DPyPE (1,2-diphytanoyl-sn-glydero-3-phosphoethanolamine).",PMID:21118032,Randi Vita|Oliver He,,,,,,,,,Th17 immune profile,
VO:0005375,T-vant vaccine adjuvant,vaccine adjuvant,"A vaccine adjuant that is derived from Salmonella enterica serovar typhimurium and is able to induce Th1/Th2/Th17 immune responses through the mechanism of action of TLR4, inflammasome, and DC activation.",https://vac.niaid.nih.gov/view?id=61|https://www.ncbi.nlm.nih.gov/pubmed/?term=33498352|https://www.ncbi.nlm.nih.gov/pubmed/?term=34069796,Lisa Morici|Wolfgang Leitner|Oliver He,T-vant,,,"Chemical Nature: other
Mechanism of Action: TLR4; inflammasome; DC activation
Immune profile induced: Th1/Th2/Th17
Receptor: TLR4, NLRP3
Storage information: -20 or -80C
Point of Contact: Lisa Morici, Tulane University",61,,"NACHT, LRR and PYD domains-containing protein 3|Toll-like receptor 4",NLRP3 receptor role|TLR4 receptor role,Th1/Th2/Th17 mixed immune profile,
VO:0005379,PIKA vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=55|https://www.ncbi.nlm.nih.gov/pubmed/?term=17484805|https://www.ncbi.nlm.nih.gov/pubmed/?term=20538850|https://www.ncbi.nlm.nih.gov/pubmed/?term=21468931|https://www.ncbi.nlm.nih.gov/pubmed/?term=26765968|https://www.ncbi.nlm.nih.gov/pubmed/?term=28118938|https://www.ncbi.nlm.nih.gov/pubmed/?term=29174316|https://www.ncbi.nlm.nih.gov/pubmed/?term=34766005,Xiaoliang Ren|Wolfgang Leitner|Oliver He,PIKA,,,"Chemical Nature: Nucleic Acid
Mechanism of Action: TLR/RLR-agonist
Immune profile induced: Th1/Th2

Route of immunization: IM and IN
Point of Contact: Xiaoliang Ren, Yisheng Bio

Ongoing clinical trial:
https://clinicaltrials.gov/ct2/show/NCT02657161
https://clinicaltrials.gov/ct2/show/NCT02956421",55,,,,Th1/Th2 mixed immune profile,
VO:0005380,Mastoparan 7 vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=53|https://www.ncbi.nlm.nih.gov/pubmed/?term=31068425|https://www.ncbi.nlm.nih.gov/pubmed/?term=32047657|https://www.ncbi.nlm.nih.gov/pubmed/?term=34566991,Herman Staats|Wolfgang Leitner|Oliver He,Mastoparan 7,,,"Chemical Nature: peptide
Mechanism of Action: activation of mast cells, epithelial cells, macrophages and dendritic cells
Immune profile induced: Th2-biased

Route of immunization: IM and IN
Point of Contact: Herman Staats, Duke University",53,,,,Th2-biased immune profile,
VO:0005381,Mast cell activator small molecules vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=54|https://www.ncbi.nlm.nih.gov/pubmed/?term=34566991,Herman Staats|Wolfgang Leitner|Oliver He,Mast cell activator small molecules,,,"Chemical Nature: small molecule
Mechanism of Action: mast cell activation
Immune profile induced: Th2-biased

Route of immunization: IN
Point of Contact: Herman Staats, Duke University",54,,,,Th2-biased immune profile,
VO:0005382,Precision Vaccines Program (PVP)-037 vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=56,Ofer Levy|Wolfgang Leitner|Oliver He,Precision Vaccines Program (PVP)-037,,,"Chemical Nature: small molecule
Mechanism of Action: Innate Immune Activation
Immune profile induced: Th1-biased

Route of immunization: IM
Point of Contact: Ofer Levy, Precision Vaccines Program at Boston Children's Hospital",56,,,,Th1-biased immune profile,
VO:0005383,BECC470s vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=60,Robert Ernst|Wolfgang Leitner|Oliver He,BECC470s,,,"Chemical Nature: small molecule
Mechanism of Action: TLR4 agonist
Immune profile induced: Th1/Th2

Route of immunization: IM and IN
Point of Contact: Robert Ernst, University of Maryland - Baltimore",60,,,,Th1/Th2 mixed immune profile,
VO:0005384,TRAC478 vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=48,Helene Bazin-Lee|Wolfgang Leitner|Oliver He,TRAC478,,,"Chemical Nature: small molecule
Mechanism of Action: innate immune activation
Immune profile induced: Th1-biased
Route of immunization: IM
Point of Contact: Helene Bazin-Lee, University of Montana",48,,,,Th1-biased immune profile,
VO:0005385,GLA-3M-052-LS vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=58|https://www.ncbi.nlm.nih.gov/pubmed/?term=34248966|https://www.ncbi.nlm.nih.gov/pubmed/?term=34795290,Christopher Fox|Wolfgang Leitner|Oliver He,GLA-3M-052-LS,,,"Chemical Nature: small molecule
Mechanism of Action: innate immune activation
Immune profile induced: Th1/Th17

Route of immunization: IM and IN
Point of Contact: Christopher Fox, AAHI",58,,,,Th1/Th17 mixed immune profile,
VO:0005386,3M-052-SE vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=57|https://www.ncbi.nlm.nih.gov/pubmed/?term=28429728|https://www.ncbi.nlm.nih.gov/pubmed/?term=30089691|https://www.ncbi.nlm.nih.gov/pubmed/?term=32213623|https://www.ncbi.nlm.nih.gov/pubmed/?term=34131024|https://www.ncbi.nlm.nih.gov/pubmed/?term=34972105|https://www.ncbi.nlm.nih.gov/pubmed/?term=35572573,Christopher Fox|Wolfgang Leitner|Oliver He,3M-052-SE,,,"Chemical Nature: small molecule
Mechanism of Action: innate immune activation
Immune profile induced: Th1-biased

Route of immunization: IM
Point of Contact: Christopher Fox, AAHI",57,,,,Th1-biased immune profile,
VO:0005387,3M-052-Alum vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=59|https://www.ncbi.nlm.nih.gov/pubmed/?term=27847326|https://www.ncbi.nlm.nih.gov/pubmed/?term=32561559|https://www.ncbi.nlm.nih.gov/pubmed/?term=33971664|https://www.ncbi.nlm.nih.gov/pubmed/?term=34117252|https://www.ncbi.nlm.nih.gov/pubmed/?term=34266981,Christopher Fox|Wolfgang Leitner|Oliver He,3M-052-Alum,,,"Chemical Nature: small molecule
Mechanism of Action: innate immune activation
Immune profile induced: Th1-biased

Route of immunization: IM
Point of Contact: Christopher Fox, AAHI

Clinical trials:
https://clinicaltrials.gov/ct2/show/NCT04177355
https://clinicaltrials.gov/ct2/show/NCT04915768
https://clinicaltrials.gov/ct2/show/NCT05197712",59,,,,Th1-biased immune profile,
VO:0005388,SWE vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=50|https://www.ncbi.nlm.nih.gov/pubmed/?term=30849373|https://www.ncbi.nlm.nih.gov/pubmed/?term=32411401,Patrice Dubois|Wolfgang Leitner|Oliver He,SWE,,,"Chemical Nature: (1) emulsion
Mechanism of Action: unknown
Immune profile induced: Th1/Th17

Route of immunization: IM
Point of Contact: Patrice Dubois, Vaccine Formulation Institute

Clinical trial:
https://clinicaltrials.gov/ct2/show/NCT04702178",50,,,,Th1/Th17 mixed immune profile,
VO:0005389,SQ vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=52|https://www.ncbi.nlm.nih.gov/pubmed/?term=33688647,Patrice Dubois|Wolfgang Leitner|Oliver He,SQ,,,"Chemical Nature: (1) Emulsion (with Saponin)
Mechanism of Action: unknown
Immune profile induced: Th1-biased

Route of immunization: IM
Point of Contact: Patrice Dubois, Vaccine Formulation Institute",52,,,,Th1-biased immune profile,
VO:0005390,LQ vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=51|https://www.ncbi.nlm.nih.gov/pubmed/?term=32156809|https://www.ncbi.nlm.nih.gov/pubmed/?term=33688647,Patrice Dubois|Wolfgang Leitner|Oliver He,LQ,,,"Chemical Nature: (1) other (liposome with Saponin)
Mechanism of Action: unknown
Immune profile induced: Th1-biased

Route of immunization: IM
Point of Contact: Patrice Dubois, Vaccine Formulation Institute",51,,,,Th1-biased immune profile,
VO:0005419,MicroCrystalline Tyrosine vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=25|https://www.ncbi.nlm.nih.gov/pubmed/?term=28347293|https://www.ncbi.nlm.nih.gov/pubmed/?term=28468322|https://www.ncbi.nlm.nih.gov/pubmed/?term=28953265|https://www.ncbi.nlm.nih.gov/pubmed/?term=29592962,Matthew Heath|Wolfgang Leitner|Oliver He|Ani Bernardi|Ari Joffe,MCT|MCT vaccine adjuvant|MicroCrystalline Tyrosine,,,"Chemical Nature: other
Mechanism of Action: Activation of APCs, activation of T cells and stimulating B cell proliferation (IgG)
Immune profile induced: Th1-biased

Route of immunization: IM and SQ
Point of Contact: Matthew Heath, Allergy Therapeutics (UK) Ltd",25,,,,Th1-biased immune profile,
VO:0005420,GLA-SE vaccine adjuvant,vaccine adjuvant,,https://clinicaltrials.gov/ct2/show/NCT01484548|https://clinicaltrials.gov/ct2/show/NCT01751048|https://clinicaltrials.gov/ct2/show/NCT02071758|https://vac.niaid.nih.gov/view?id=62|https://www.ncbi.nlm.nih.gov/pubmed/?term=20944089|https://www.ncbi.nlm.nih.gov/pubmed/?term=21060869|https://www.ncbi.nlm.nih.gov/pubmed/?term=27142329,Christopher Fox|Wolfgang Leitner|Oliver He|Ani Bernardi|Ari Joffe,GLA-SE,,,"Chemical Nature: other
Mechanism of Action: TLR4; Innate Immune Activation
Immune profile induced: Th1-biased

Route of immunization: IM
Point of Contact: Christopher Fox, AAHI

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=27142329
https://www.ncbi.nlm.nih.gov/pubmed/?term=21060869
https://www.ncbi.nlm.nih.gov/pubmed/?term=20944089
https://www.ncbi.nlm.nih.gov/pubmed/?term=20944089
https://www.ncbi.nlm.nih.gov/pubmed/?term=20944089
https://www.ncbi.nlm.nih.gov/pubmed/?term=21816196
https://www.ncbi.nlm.nih.gov/pubmed/?term=21690242
https://www.ncbi.nlm.nih.gov/pubmed/?term=21060869
https://www.ncbi.nlm.nih.gov/pubmed/?term=22291184
https://www.ncbi.nlm.nih.gov/pubmed/?term=22291184
https://www.ncbi.nlm.nih.gov/pubmed/?term=23045649
https://www.ncbi.nlm.nih.gov/pubmed/?term=23045649
https://www.ncbi.nlm.nih.gov/pubmed/?term=22509423
https://www.ncbi.nlm.nih.gov/pubmed/?term=22896687
https://www.ncbi.nlm.nih.gov/pubmed/?term=23904160
https://www.ncbi.nlm.nih.gov/pubmed/?term=23954378
https://www.ncbi.nlm.nih.gov/pubmed/?term=22425788
https://www.ncbi.nlm.nih.gov/pubmed/?term=22891286
https://www.ncbi.nlm.nih.gov/pubmed/?term=22891286
https://www.ncbi.nlm.nih.gov/pubmed/?term=23624057
https://www.ncbi.nlm.nih.gov/pubmed/?term=23624057
https://www.ncbi.nlm.nih.gov/pubmed/?term=23228811
https://www.ncbi.nlm.nih.gov/pubmed/?term=25024362
https://www.ncbi.nlm.nih.gov/pubmed/?term=25030053
https://www.ncbi.nlm.nih.gov/pubmed/?term=24404140
https://www.ncbi.nlm.nih.gov/pubmed/?term=24556505
https://www.ncbi.nlm.nih.gov/pubmed/?term=24556505
https://www.ncbi.nlm.nih.gov/pubmed/?term=24397898
https://www.ncbi.nlm.nih.gov/pubmed/?term=24397898
https://www.ncbi.nlm.nih.gov/pubmed/?term=24728521
https://www.ncbi.nlm.nih.gov/pubmed/?term=24728521
https://www.ncbi.nlm.nih.gov/pubmed/?term=25367751
https://www.ncbi.nlm.nih.gov/pubmed/?term=26541135
https://www.ncbi.nlm.nih.gov/pubmed/?term=25637347
https://www.ncbi.nlm.nih.gov/pubmed/?term=27005808
https://www.ncbi.nlm.nih.gov/pubmed/?term=26656121
https://www.ncbi.nlm.nih.gov/pubmed/?term=26874325
https://www.ncbi.nlm.nih.gov/pubmed/?term=26791076
https://www.ncbi.nlm.nih.gov/pubmed/?term=27466350
https://www.ncbi.nlm.nih.gov/pubmed/?term=27699241
https://www.ncbi.nlm.nih.gov/pubmed/?term=29176865
https://www.ncbi.nlm.nih.gov/pubmed/?term=27958370
https://www.ncbi.nlm.nih.gov/pubmed/?term=29263879
https://www.ncbi.nlm.nih.gov/pubmed/?term=29795025
https://www.ncbi.nlm.nih.gov/pubmed/?term=29983563
https://www.ncbi.nlm.nih.gov/pubmed/?term=29619252
https://www.ncbi.nlm.nih.gov/pubmed/?term=29619252
https://www.ncbi.nlm.nih.gov/pubmed/?term=27895131
https://www.ncbi.nlm.nih.gov/pubmed/?term=32636844
https://www.ncbi.nlm.nih.gov/pubmed/?term=29541075
https://www.ncbi.nlm.nih.gov/pubmed/?term=33705411
https://www.ncbi.nlm.nih.gov/pubmed/?term=35126135
https://www.ncbi.nlm.nih.gov/pubmed/?term=19679214
https://www.ncbi.nlm.nih.gov/pubmed/?term=26731269
https://www.ncbi.nlm.nih.gov/pubmed/?term=26453448
https://www.ncbi.nlm.nih.gov/pubmed/?term=26453448
https://www.ncbi.nlm.nih.gov/pubmed/?term=27456709
https://www.ncbi.nlm.nih.gov/pubmed/?term=32023469
https://www.ncbi.nlm.nih.gov/pubmed/?term=32402293
https://www.ncbi.nlm.nih.gov/pubmed/?term=32348377
https://www.ncbi.nlm.nih.gov/pubmed/?term=32697993
https://www.ncbi.nlm.nih.gov/pubmed/?term=29515589
https://www.ncbi.nlm.nih.gov/pubmed/?term=33046728
https://www.ncbi.nlm.nih.gov/pubmed/?term=31690678
https://www.ncbi.nlm.nih.gov/pubmed/?term=31174937
https://www.ncbi.nlm.nih.gov/pubmed/?term=30567978
https://www.ncbi.nlm.nih.gov/pubmed/?term=31362695
https://www.ncbi.nlm.nih.gov/pubmed/?term=29769270
https://www.ncbi.nlm.nih.gov/pubmed/?term=31521953
https://www.ncbi.nlm.nih.gov/pubmed/?term=28298421

Ongoing clinical trial:
https://clinicaltrials.gov/ct2/show/NCT01484548
https://clinicaltrials.gov/ct2/show/NCT01751048
https://clinicaltrials.gov/ct2/show/NCT02071758
https://clinicaltrials.gov/ct2/show/NCT02465216
https://clinicaltrials.gov/ct2/show/NCT01927159
https://clinicaltrials.gov/ct2/show/NCT01599897
https://clinicaltrials.gov/ct2/show/NCT01154049
https://clinicaltrials.gov/ct2/show/NCT03302897
https://clinicaltrials.gov/ct2/show/NCT02465216
https://clinicaltrials.gov/ct2/show/NCT02508376
https://clinicaltrials.gov/ct2/show/NCT03806686
https://clinicaltrials.gov/ct2/show/NCT01949909
https://clinicaltrials.gov/ct2/show/NCT01540474
https://clinicaltrials.gov/ct2/show/NCT02014727
https://clinicaltrials.gov/ct2/show/NCT02647489
https://clinicaltrials.gov/ct2/show/NCT02658253
https://clinicaltrials.gov/ct2/show/NCT01991561
https://clinicaltrials.gov/ct2/show/NCT01596725
https://clinicaltrials.gov/ct2/show/NCT01147068
https://clinicaltrials.gov/ct2/show/NCT03820414
https://clinicaltrials.gov/ct2/show/NCT03220724
https://clinicaltrials.gov/ct2/show/NCT03409276
https://clinicaltrials.gov/ct2/show/NCT01864876
https://clinicaltrials.gov/ct2/show/NCT02115815
https://clinicaltrials.gov/ct2/show/NCT01397604",62,,,,,
VO:0005421,GLA-SLQ vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=63|https://www.ncbi.nlm.nih.gov/pubmed/?term=22896687|https://www.ncbi.nlm.nih.gov/pubmed/?term=24465426|https://www.ncbi.nlm.nih.gov/pubmed/?term=24551202|https://www.ncbi.nlm.nih.gov/pubmed/?term=24556505|https://www.ncbi.nlm.nih.gov/pubmed/?term=26541135|https://www.ncbi.nlm.nih.gov/pubmed/?term=26862758|https://www.ncbi.nlm.nih.gov/pubmed/?term=31174937|https://www.ncbi.nlm.nih.gov/pubmed/?term=31690678|https://www.ncbi.nlm.nih.gov/pubmed/?term=32636844,Christopher Fox|Wolfgang Leitner|Oliver He|Ani Bernardi|Ari Joffe,GLA-SLQ,,,"Chemical Nature: other
Mechanism of Action: TLR4; Innate Immune Activation
Immune profile induced: Mixed Th1/Th2

Route of immunization: IM
Point of Contact: Christopher Fox, AAHI

Ongoing clinical trial:
https://clinicaltrials.gov/ct2/show/NCT02508376
https://clinicaltrials.gov/ct2/show/NCT02647489
https://clinicaltrials.gov/ct2/show/NCT04177355
https://clinicaltrials.gov/ct2/show/NCT03589794",63,,,TLR4 receptor role,Th1/Th2 mixed immune profile,
VO:0005422,SLA-LSQ vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=64|https://www.ncbi.nlm.nih.gov/pubmed/?term=30302281,Christopher Fox|Wolfgang Leitner|Oliver He|Ani Bernardi|Ari Joffe,SLA-LSQ,,,"Chemical Nature: other
Mechanism of Action: TLR4; Innate Immune Activation
Immune profile induced: Th1-biased

Route of immunization: IM
Point of Contact: Christopher Fox, AAHI",64,,,TLR4 receptor role,Th1-biased immune profile,
VO:0005423,SLA-SE vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=65|https://www.ncbi.nlm.nih.gov/pubmed/?term=30386348|https://www.ncbi.nlm.nih.gov/pubmed/?term=31149350|https://www.ncbi.nlm.nih.gov/pubmed/?term=31891152|https://www.ncbi.nlm.nih.gov/pubmed/?term=32540272|https://www.ncbi.nlm.nih.gov/pubmed/?term=35459225,Christopher Fox|Wolfgang Leitner|Oliver He|Ani Bernardi|Ari Joffe,SLA-SE,,,"Chemical Nature: other
Mechanism of Action: TLR4; Innate Immune Activation
Immune profile induced: n/a

Route of immunization: IM
Point of Contact: Christopher Fox, AAHI

Ongoing clinical trial:
https://clinicaltrials.gov/ct2/show/NCT03820414
https://clinicaltrials.gov/ct2/show/NCT02071758",65,,,TLR4 receptor role,,
VO:0005424,GLA-AF vaccine adjuvant,vaccine adjuvant,,https://vac.niaid.nih.gov/view?id=66|https://www.ncbi.nlm.nih.gov/pubmed/?term=22896687|https://www.ncbi.nlm.nih.gov/pubmed/?term=24465426|https://www.ncbi.nlm.nih.gov/pubmed/?term=24551202|https://www.ncbi.nlm.nih.gov/pubmed/?term=24556505|https://www.ncbi.nlm.nih.gov/pubmed/?term=26541135|https://www.ncbi.nlm.nih.gov/pubmed/?term=26862758|https://www.ncbi.nlm.nih.gov/pubmed/?term=31174937|https://www.ncbi.nlm.nih.gov/pubmed/?term=31690678|https://www.ncbi.nlm.nih.gov/pubmed/?term=32636844,Christopher Fox|Wolfgang Leitner|Oliver He|Ani Bernardi|Ari Joffe,GLA-AF,,,"Chemical Nature: other
Mechanism of Action: TLR4; Innate Immune Activation
Immune profile induced: Th1-biased

Route of immunization: IM
Point of Contact: Christopher Fox, AAHI

Ongoing clinical trial:
https://clinicaltrials.gov/ct2/show/NCT02508376
https://clinicaltrials.gov/ct2/show/NCT02647489
https://clinicaltrials.gov/ct2/show/NCT04177355
https://clinicaltrials.gov/ct2/show/NCT03589794",66,,,TLR4 receptor role,Th1-biased immune profile,
VO:0005471,MAS-1 vaccine adjuvant,vaccine adjuvant,A vaccine adjuvant 30:70 (w/w) Water-in-Oil  (W/O) emulsion that stimulates a mixed Th1/Th2 response.,https://clinicaltrials.gov/ct2/show/NCT02118077|https://clinicaltrials.gov/ct2/show/NCT02500680|https://clinicaltrials.gov/ct2/show/NCT03624062|https://vac.niaid.nih.gov/view?id=68|https://www.ncbi.nlm.nih.gov/pubmed/?term=23595760|https://www.ncbi.nlm.nih.gov/pubmed/?term=24783964|https://www.ncbi.nlm.nih.gov/pubmed/?term=34429319|https://www.ncbi.nlm.nih.gov/pubmed/?term=34926305,Peter Blackburn|Ari Joffe|Wolfgang Leitner|Oliver He,MAS-1,,,"Chemical Nature: emulsion
Mechanism of Action: adjuvanted antigen depot at injection site
Immune profile induced: Mixed Th1/Th2

Route of immunization: IM and SQ
Point of Contact: Peter Blackburn, MerciaPharma

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=23595760
https://www.ncbi.nlm.nih.gov/pubmed/?term=24783964
https://www.ncbi.nlm.nih.gov/pubmed/?term=34429319
https://www.ncbi.nlm.nih.gov/pubmed/?term=34926305

Ongoing clinical trials:
https://clinicaltrials.gov/ct2/show/NCT02500680
https://clinicaltrials.gov/ct2/show/NCT02500680
https://clinicaltrials.gov/ct2/show/NCT03624062
https://clinicaltrials.gov/ct2/show/NCT02118077",68,,,,Th1/Th2 mixed immune profile,
VO:0005472,ProLNG-S vaccine adjuvant,vaccine adjuvant,A vaccine adjuvant that induces CD8 T cells and provides innate protection.,https://vac.niaid.nih.gov/view?id=34|https://www.ncbi.nlm.nih.gov/pubmed/?term=36635335,Taegyan Kang|Ari Joffe|Wolfgang Leitner|Oliver He,ProLNG-S,,,"Chemical Nature: small molecule
Mechanism of Action: Innate Immune Activation
Immune profile induced: Th1-biased

Route of immunization: SQ
Point of Contact: Taegyan Kang, Progeneer

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=36635335

Ongoing clinical trials: n/a",34,,,,Th1-biased immune profile,
VO:0005473,CAF09b vaccine adjuvant,vaccine adjuvant,A vaccine adjuvant that is a lipid-based vaccine adjuvent based on cationic surfactant dimethyl-dioctadecyl ammonium (DDA) combined with C-type lectin agonist monomycoloyl glycerol (MMG) and TLR3 agonist poly I:C. CAF09b is able to induce CD8+ T-cell response.,https://clinicaltrials.gov/ct2/show/NCT03715985|https://vac.niaid.nih.gov/view?id=76|https://www.ncbi.nlm.nih.gov/pubmed/?term=33352684|https://www.ncbi.nlm.nih.gov/pubmed/?term=35036074|https://www.ncbi.nlm.nih.gov/pubmed/?term=35163772,Gabriel Kristian Pedersen|Ari Joffe|Wolfgang Leitner|Oliver He,CAF09b,,,"Chemical Nature: Liposome
Mechanism of Action: n/a
Immune profile induced: n/a

Route of immunization: IN, IP, IM,
Point of Contact: Gabriel Kristian Pedersen, Staten Serum Institute (SSI)

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=35163772
https://www.ncbi.nlm.nih.gov/pubmed/?term=33352684
https://www.ncbi.nlm.nih.gov/pubmed/?term=35036074

Ongoing clinical trials:
https://clinicaltrials.gov/ct2/show/NCT03715985",76,,,,Th1-biased immune profile,
VO:0005474,3M-052-AF vaccine adjuvant,vaccine adjuvant,A vaccine adjuvant that is a lipid-based nanosuspension of a synthetic TLR7/8 ligand that facilitates adsorption to aluminum oxyhydroxide via the structural properties of the helper lipid employed.,https://clinicaltrials.gov/ct2/show/NCT04177355|https://clinicaltrials.gov/ct2/show/NCT04915768|https://clinicaltrials.gov/ct2/show/NCT05471076|https://clinicaltrials.gov/ct2/show/NCT05781542|https://vac.niaid.nih.gov/view?id=69|https://www.ncbi.nlm.nih.gov/pubmed/?term=27847326|https://www.ncbi.nlm.nih.gov/pubmed/?term=36274085,Valerie Soza|Ari Joffe|Wolfgang Leitner|Oliver He,3M-052-AF,,,"Chemical Nature: Small molecule
Mechanism of Action: Innate Immune Activation
Immune profile induced: Th1-biased

Route of immunization: IM
Point of Contact: Valerie Soza, AAHI

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=27847326
https://www.ncbi.nlm.nih.gov/pubmed/?term=27847326
https://www.ncbi.nlm.nih.gov/pubmed/?term=36274085

Ongoing clinical trials:
https://clinicaltrials.gov/ct2/show/NCT04177355
https://clinicaltrials.gov/ct2/show/NCT05781542
https://clinicaltrials.gov/ct2/show/NCT05471076
https://clinicaltrials.gov/ct2/show/NCT04915768
https://clinicaltrials.gov/ct2/show/NCT05781542",69,,,,Th1-biased immune profile,
VO:0005475,NanoAlum vaccine adjuvant,vaccine adjuvant,"A vaccine adjuvant that reformulates Alhydrogel as a stable nanoparticle with the anionic polymer polyacrylic acid (PAA), leading to the induction of structure-dependent TH1 response.",https://vac.niaid.nih.gov/view?id=71|https://www.ncbi.nlm.nih.gov/pubmed/?term=30622742|https://www.ncbi.nlm.nih.gov/pubmed/?term=31930264,Valerie Soza|Ari Joffe|Wolfgang Leitner|Oliver He,NanoAlum,,,"Chemical Nature: Small molecule
Mechanism of Action: Innate Immune Activation
Immune profile induced: Th1-biased

Route of immunization: IM
Point of Contact: Valerie Soza, AAHI

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=30622742
https://www.ncbi.nlm.nih.gov/pubmed/?term=31930264",71,,,,Th1-biased immune profile,
VO:0005476,Nanostructured Lipid Carrier (NLC) vaccine adjuvant,vaccine adjuvant,A vaccine adjuvant is a small molecule adjuvant that induces Th1-based immune response and is designed for use with self-amplifying RNA antigens.,https://clinicaltrials.gov/ct2/show/NCT05370040|https://vac.niaid.nih.gov/view?id=70|https://www.ncbi.nlm.nih.gov/pubmed/?term=24551202|https://www.ncbi.nlm.nih.gov/pubmed/?term=34058388|https://www.ncbi.nlm.nih.gov/pubmed/?term=35308783|https://www.ncbi.nlm.nih.gov/pubmed/?term=35911728|https://www.ncbi.nlm.nih.gov/pubmed/?term=36323666|https://www.ncbi.nlm.nih.gov/pubmed/?term=36589712,Valerie Soza|Ari Joffe|Wolfgang Leitner|Oliver He,NLC vaccine adjuvant|Nanostructured Lipid Carrier|Nanostructured Lipid Carrier (NLC),,,"Chemical Nature: Small molecule
Mechanism of Action: Innate Immune Activation
Immune profile induced: Th1-biased

Route of immunization: IM
Point of Contact: Valerie Soza, AAHI

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=35911728
https://www.ncbi.nlm.nih.gov/pubmed/?term=24551202
https://www.ncbi.nlm.nih.gov/pubmed/?term=34058388
https://www.ncbi.nlm.nih.gov/pubmed/?term=35308783
https://www.ncbi.nlm.nih.gov/pubmed/?term=36589712
https://www.ncbi.nlm.nih.gov/pubmed/?term=36323666

Ongoing clinical trials:
https://clinicaltrials.gov/ct2/show/NCT05370040",70,,,,Th1-biased immune profile,
VO:0005482,SLA-AF vaccine adjuvant,vaccine adjuvant,A vaccine adjuvant is an oil-in-water emulsion that induces Th1-based immune response.,https://vac.niaid.nih.gov/view?id=72|https://www.ncbi.nlm.nih.gov/pubmed/?term=32983577|https://www.ncbi.nlm.nih.gov/pubmed/?term=35459225,Valerie Soza|Ari Joffe|Wolfgang Leitner|Oliver He,SLA-AF,,,"Chemical Nature: Small molecule
Mechanism of Action: Innate Immune Activation
Immune profile induced: n/a

Route of immunization: IM
Point of Contact: Valerie Soza, AAHI

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=32983577
https://www.ncbi.nlm.nih.gov/pubmed/?term=35459225",72,,,,Th1-biased immune profile,
VO:0005483,CAF01 vaccine adjuvant,vaccine adjuvant,A vaccine adjuvant is a gadoteridol-loaded cationic adjuvant formulation 01 that induced a Th1/Th17 type of immune response.,https://clinicaltrials.gov/ct2/show/NCT00922363|https://clinicaltrials.gov/ct2/show/NCT01009762|https://clinicaltrials.gov/ct2/show/NCT01141205|https://clinicaltrials.gov/ct2/show/NCT02787109|https://clinicaltrials.gov/ct2/show/NCT03926728|https://vac.niaid.nih.gov/view?id=75|https://www.ncbi.nlm.nih.gov/pubmed/?term=18776936|https://www.ncbi.nlm.nih.gov/pubmed/?term=21124731|https://www.ncbi.nlm.nih.gov/pubmed/?term=26394776|https://www.ncbi.nlm.nih.gov/pubmed/?term=29358939|https://www.ncbi.nlm.nih.gov/pubmed/?term=29699790|https://www.ncbi.nlm.nih.gov/pubmed/?term=30291987|https://www.ncbi.nlm.nih.gov/pubmed/?term=30555488|https://www.ncbi.nlm.nih.gov/pubmed/?term=31539263|https://www.ncbi.nlm.nih.gov/pubmed/?term=34044110,Gabriel Kristian Pedersen|Ari Joffe|Wolfgang Leitner|Oliver He,CAF01,,,"Chemical Nature: Liposome system
Mechanism of Action: n/a
Immune profile induced: Th1/Th17

Route of immunization: IP, IM, IN, SQ, ID, SC, SL, intratracheal, endotracheal, Fish vaccination
Point of Contact: Gabriel Kristian Pedersen, Staten Serum Institute (SSI)

Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=31539263
https://www.ncbi.nlm.nih.gov/pubmed/?term=30555488
https://www.ncbi.nlm.nih.gov/pubmed/?term=29699790
https://www.ncbi.nlm.nih.gov/pubmed/?term=34044110
https://www.ncbi.nlm.nih.gov/pubmed/?term=26394776
https://www.ncbi.nlm.nih.gov/pubmed/?term=18776936
https://www.ncbi.nlm.nih.gov/pubmed/?term=30291987
https://www.ncbi.nlm.nih.gov/pubmed/?term=21124731
https://www.ncbi.nlm.nih.gov/pubmed/?term=29358939
https://www.ncbi.nlm.nih.gov/pubmed/?term=33072125
https://www.ncbi.nlm.nih.gov/pubmed/?term=35585969
https://www.ncbi.nlm.nih.gov/pubmed/?term=26494626
https://www.ncbi.nlm.nih.gov/pubmed/?term=26379666
https://www.ncbi.nlm.nih.gov/pubmed/?term=35124896
https://www.ncbi.nlm.nih.gov/pubmed/?term=34358167
https://www.ncbi.nlm.nih.gov/pubmed/?term=29541075
https://www.ncbi.nlm.nih.gov/pubmed/?term=31130946
https://www.ncbi.nlm.nih.gov/pubmed/?term=31906072
https://www.ncbi.nlm.nih.gov/pubmed/?term=32106599
https://www.ncbi.nlm.nih.gov/pubmed/?term=19492047
https://www.ncbi.nlm.nih.gov/pubmed/?term=33422991
https://www.ncbi.nlm.nih.gov/pubmed/?term=28414746
https://www.ncbi.nlm.nih.gov/pubmed/?term=33066267
https://www.ncbi.nlm.nih.gov/pubmed/?term=27958370
https://www.ncbi.nlm.nih.gov/pubmed/?term=23308247
https://www.ncbi.nlm.nih.gov/pubmed/?term=30984200
https://www.ncbi.nlm.nih.gov/pubmed/?term=20505822
https://www.ncbi.nlm.nih.gov/pubmed/?term=27525651
https://www.ncbi.nlm.nih.gov/pubmed/?term=23873630

Ongoing clinical trials:
https://clinicaltrials.gov/ct2/show/NCT00922363
https://clinicaltrials.gov/ct2/show/NCT01009762
https://clinicaltrials.gov/ct2/show/NCT02787109
https://clinicaltrials.gov/ct2/show/NCT01141205
https://clinicaltrials.gov/ct2/show/NCT03926728",75,,,,Th1/Th17 mixed immune profile,
VO:0006092,LMQ vaccine adjuvant,combination vaccine adjuvant,A combination vaccine adjuvant that induced a Th1-biased immune response.,https://www.ncbi.nlm.nih.gov/pubmed/?term=36634821|https://www.ncbi.nlm.nih.gov/pubmed/?term=36119058|https://www.ncbi.nlm.nih.gov/pubmed/?term=37029167,Maria Lawrenz|Jie Zheng|Wolfgang Leitner|Oliver He|Nilufer kosar,LMQ,,,"Chemical Nature: Combination adjuvant
Mechanism of Action: n/a
Immune profile induced: Th1-biased
Route of immunization: IM
Point of Contact: Maria Lawrenz, Vaccine Formulation Institute",78,https://github.com/vaccineontology/VO/issues/614,,,Th1-biased immune profile,
VO:0006093,CPDI-02 vaccine adjuvant,vaccine adjuvant,A vaccine adjuvant that is a peptide which is able to induce Th1/Th2/Th17 immune responses through the mechanism of selectively activates C5aR1 on mononuclear phagocytes vs neutrophils.,https://www.ncbi.nlm.nih.gov/pubmed/?term=11710544|https://www.ncbi.nlm.nih.gov/pubmed/?term=19836478|https://www.ncbi.nlm.nih.gov/pubmed/?term=20965299,Joseph Vetro|Jie Zheng|Wolfgang Leitner|Oliver He|Nilufer kosar,CPDI-02,,,"Chemical Nature: Other - Peptide
Mechanism of Action: (Primary) Selectively activates C5aR1 on mononuclear phagocytes vs neutrophils
Immune profile induced: Th1/Th2/Th17
Route of immunization: IP, IV
Point of Contact: Joseph Vetro, University of Nebraska Medical Center",40,https://github.com/vaccineontology/VO/issues/615,,,Th1/Th2/Th17 mixed immune profile,
VO:0006094,CpG55.2 vaccine adjuvant,vaccine adjuvant,A vaccine adjuvant with a Toll-like receptor 9 (TLR9)-active oligonucleotide that is able to induce Th1/Th2 immune responses.,https://www.ncbi.nlm.nih.gov/pubmed/?term=34420786|https://www.ncbi.nlm.nih.gov/pubmed/?term=34399628|https://www.ncbi.nlm.nih.gov/pubmed/?term=34456075|https://www.ncbi.nlm.nih.gov/pubmed/?term=34420786|https://www.ncbi.nlm.nih.gov/pubmed/?term=24554695|https://www.ncbi.nlm.nih.gov/pubmed/?term=32418798|https://www.ncbi.nlm.nih.gov/pubmed/?term=32156809|https://www.ncbi.nlm.nih.gov/pubmed/?term=33479242|https://www.ncbi.nlm.nih.gov/pubmed/?term=27387453,Nikolai Petrovsky|Jie Zheng|Wolfgang Leitner|Oliver He|Nilufer kosar,CpG55.2,,,"Chemical Nature: Nucleic acid
Mechanism of Action: TLR9 agonist
Immune profile induced: Mixed Th1/Th2
Route of immunization: IM, SQ
Point of Contact: Nikolai Petrovsky, Vaxine LTD
",10,https://github.com/vaccineontology/VO/issues/616,,,Th1/Th2 mixed immune profile,
VO:0006095,SMNP vaccine adjuvant,combination vaccine adjuvant,,,Katarzyna Kaczmarek Michaels|Jie Zheng|Wolfgang Leitner|Oliver He|Nilufer kosar,SMNP,,,"Chemical Nature: Combination adjuvant
Mechanism of Action: Cytokine induction in draining lymph nodes with increased lymph flow and lymph antigen accumulation
Immune profile induced: Mixed Th1/Th2
Route of immunization: s.c. / i.m. / i.n.
Point of Contact: Katarzyna Kaczmarek Michaels, Massachusetts Institute of Technology
Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=34860581
https://www.ncbi.nlm.nih.gov/pubmed/?term=36131022
https://www.ncbi.nlm.nih.gov/pubmed/?term=34878851",77,https://github.com/vaccineontology/VO/issues/632,,,Th1/Th2 mixed immune profile,
VO:0006096,ALFQ vaccine adjuvant,combination vaccine adjuvant,,,Mangala Rao|Jie Zheng|Wolfgang Leitner|Oliver He|Nilufer kosar,ALFQ,,,"Chemical Nature:
- Natural compound
- Synthetic derivative of natural compound
- Combination adjuvant
Mechanism of Action: MPLA: TLR4 agonist QS21: Sugar-lawn likely recog. by lectins to facilitate uptake by M_, DCs, etc
Immune profile induced: Mixed Th1/Th2
Route of immunization: ID, IM
Point of Contact: Mangala Rao, Walter Reed Army Institute of Research
Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=34202178
https://www.ncbi.nlm.nih.gov/pubmed/?term=31827000
https://www.ncbi.nlm.nih.gov/pubmed/?term=34470866
https://www.ncbi.nlm.nih.gov/pubmed/?term=35632473
https://www.ncbi.nlm.nih.gov/pubmed/?term=36417525
https://www.ncbi.nlm.nih.gov/pubmed/?term=34914540
https://www.ncbi.nlm.nih.gov/pubmed/?term=32881968
https://www.ncbi.nlm.nih.gov/pubmed/?term=26372857
https://www.ncbi.nlm.nih.gov/pubmed/?term=36055874
https://www.ncbi.nlm.nih.gov/pubmed/?term=34202178
https://www.ncbi.nlm.nih.gov/pubmed/?term=36679887
https://www.ncbi.nlm.nih.gov/pubmed/?term=36934088
https://www.ncbi.nlm.nih.gov/pubmed/?term=34903722
https://www.ncbi.nlm.nih.gov/pubmed/?term=31775762
https://www.ncbi.nlm.nih.gov/pubmed/?term=28596090
https://www.ncbi.nlm.nih.gov/pubmed/?term=31151801
https://www.ncbi.nlm.nih.gov/pubmed/?term=34711815
https://www.ncbi.nlm.nih.gov/pubmed/?term=34159328
Ongoing clinical trials:
https://clinicaltrials.gov/ct2/show/NCT04268420
https://clinicaltrials.gov/ct2/show/NCT04296279
https://clinicaltrials.gov/ct2/show/NCT04784767
https://clinicaltrials.gov/ct2/show/NCT05500417
https://clinicaltrials.gov/ct2/show/NCT04826094
https://clinicaltrials.gov/ct2/show/NCT04658667
https://clinicaltrials.gov/ct2/show/NCT05423418",79,https://github.com/vaccineontology/VO/issues/633,,,Th1/Th2 mixed immune profile,
VO:0006097,2G023A vaccine adjuvant,vaccine adjuvant,,,Dennis Carson|Jie Zheng|Wolfgang Leitner|Oliver He|Nilufer kosar,2G023A,,,"Chemical Nature:
Small molecule
Mechanism of Action: Innate immune activation
Immune profile induced: Mixed Th1/Th2
Route of immunization: IM
Point of Contact: Dennis Carson, UCSD",81,https://github.com/vaccineontology/VO/issues/648,,,Th1/Th2 mixed immune profile,
VO:0006098,2G053 vaccine adjuvant,vaccine adjuvant,,,Dennis Carson|Jie Zheng|Wolfgang Leitner|Oliver He|Nilufer kosar,2G053,,,"Chemical Nature:
Small molecule
Mechanism of Action: Innate immune activation
Immune profile induced: Mixed Th1/Th2
Route of immunization: IM
Point of Contact: Dennis Carson, UCSD",80,https://github.com/vaccineontology/VO/issues/649,,,Th1/Th2 mixed immune profile,
VO:0006099,GLA-Alum vaccine adjuvant,combination vaccine adjuvant,,,Valerie Soza|Jie Zheng|Wolfgang Leitner|Oliver He|Nilufer kosar,GLA-Alum,,,"Chemical Nature:
- Synthetic derivative of natural compound
- Combination adjuvant
- Mineral salt
Mechanism of Action: Innate Immune Activation
Immune profile induced: Th1-biased
Route of immunization: SQ, IM
Point of Contact: Valerie Soza, Access to Advanced Health Institute (AAHI)
Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=37454145
https://www.ncbi.nlm.nih.gov/pubmed/?term=24556505
https://www.ncbi.nlm.nih.gov/pubmed/?term=28828575
https://www.ncbi.nlm.nih.gov/pubmed/?term=30013570
https://www.ncbi.nlm.nih.gov/pubmed/?term=24211167
https://www.ncbi.nlm.nih.gov/pubmed/?term=23933525
https://www.ncbi.nlm.nih.gov/pubmed/?term=34597297
https://www.ncbi.nlm.nih.gov/pubmed/?term=36996185
https://www.ncbi.nlm.nih.gov/pubmed/?term=28464026
Ongoing clinical trials:
https://clinicaltrials.gov/ct2/show/NCT03910972
https://clinicaltrials.gov/ct2/show/NCT02126462
https://clinicaltrials.gov/ct2/show/NCT02839161
https://clinicaltrials.gov/ct2/show/NCT03110757
https://clinicaltrials.gov/ct2/show/NCT02337855
https://clinicaltrials.gov/ct2/show/NCT01717950
https://clinicaltrials.gov/ct2/show/NCT02476773
https://clinicaltrials.gov/ct2/show/NCT01261130
https://clinicaltrials.gov/ct2/show/NCT01385189
https://clinicaltrials.gov/ct2/show/NCT03172975",83,https://github.com/vaccineontology/VO/issues/650,,,Th1-biased immune profile,
VO:0006100,SLA-Alum vaccine adjuvant,combination vaccine adjuvant,,,Valerie Soza|Jie Zheng|Wolfgang Leitner|Oliver He|Nilufer kosar,SLA-Alum,,,"Chemical Nature:
- Synthetic derivative of natural compound
- Combination adjuvant
- Mineral salt
Mechanism of Action: Innate Immune Activation
Immune profile induced: Th1-biased
Route of immunization: IM
Point of Contact: Valerie Soza, Access to Advanced Health Institute (AAHI)
Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=26901122
https://www.ncbi.nlm.nih.gov/pubmed/?term=32983577",82,https://github.com/vaccineontology/VO/issues/651,,,Th1-biased immune profile,
VO:0006101,Stable Emulsion (SE) vaccine adjuvant,emulsion vaccine adjuvant,,,Valerie Soza|Jie Zheng|Wolfgang Leitner|Oliver He|Nilufer kosar,Stable Emulsion (SE),,,"Chemical Nature: Emulsion
Mechanism of Action: n/a
Immune profile induced: Mixed Th1/Th2
Route of immunization: IM, SQ
Point of Contact: Valerie Soza, Access to Advanced Health Institute (AAHI)
Pubmed References:
https://www.ncbi.nlm.nih.gov/pubmed/?term=19679214
https://www.ncbi.nlm.nih.gov/pubmed/?term=22896687
https://www.ncbi.nlm.nih.gov/pubmed/?term=28429728
https://www.ncbi.nlm.nih.gov/pubmed/?term=37495191
https://www.ncbi.nlm.nih.gov/pubmed/?term=36256646
https://www.ncbi.nlm.nih.gov/pubmed/?term=28089141
Ongoing clinical trials:
https://clinicaltrials.gov/ct2/show/NCT03330899
https://clinicaltrials.gov/ct2/show/NCT01612000
https://clinicaltrials.gov/ct2/show/NCT02464163
https://clinicaltrials.gov/ct2/show/NCT02464163",84,https://github.com/vaccineontology/VO/issues/652,,,Th1/Th2 mixed immune profile,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,